US5994041A
(en)
*
|
1985-04-06 |
1999-11-30 |
Eastman Kodak Company |
Process for buffering concentrated aqueous slurries
|
US5552154A
(en)
|
1989-11-06 |
1996-09-03 |
The Stehlin Foundation For Cancer Research |
Method for treating cancer with water-insoluble s-camptothecin of the closed lactone ring form and derivatives thereof
|
AU642066B2
(en)
*
|
1991-01-25 |
1993-10-07 |
Nanosystems L.L.C. |
X-ray contrast compositions useful in medical imaging
|
US5399363A
(en)
*
|
1991-01-25 |
1995-03-21 |
Eastman Kodak Company |
Surface modified anticancer nanoparticles
|
US5552160A
(en)
*
|
1991-01-25 |
1996-09-03 |
Nanosystems L.L.C. |
Surface modified NSAID nanoparticles
|
SE9101090D0
(sv)
*
|
1991-04-11 |
1991-04-11 |
Astra Ab |
Process for conditioning of water-soluble substances
|
US5766635A
(en)
*
|
1991-06-28 |
1998-06-16 |
Rhone-Poulenc Rorer S.A. |
Process for preparing nanoparticles
|
US5811447A
(en)
|
1993-01-28 |
1998-09-22 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6515009B1
(en)
|
1991-09-27 |
2003-02-04 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5342609A
(en)
*
|
1991-10-22 |
1994-08-30 |
Mallinckrodt Medical, Inc. |
Microfluidization of calcium/oxyanion-containing particles
|
US5344640A
(en)
*
|
1991-10-22 |
1994-09-06 |
Mallinckrodt Medical, Inc. |
Preparation of apatite particles for medical diagnostic imaging
|
US5407659A
(en)
*
|
1991-10-22 |
1995-04-18 |
Mallinckrodt Medical, Inc. |
Treated calcium/oxyanion-containing particles for medical diagnostic imaging
|
US5916540A
(en)
*
|
1994-10-24 |
1999-06-29 |
Glaxo Group Limited |
Aerosol formulations containing P134A and/or P227 and particulate medicament
|
US7105152B1
(en)
|
1991-12-18 |
2006-09-12 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
US7101534B1
(en)
|
1991-12-18 |
2006-09-05 |
3M Innovative Properties Company |
Suspension aerosol formulations
|
WO1993011747A1
(en)
*
|
1991-12-18 |
1993-06-24 |
Minnesota Mining And Manufacturing Company |
Suspension aerosol formulations
|
US6080751A
(en)
*
|
1992-01-14 |
2000-06-27 |
The Stehlin Foundation For Cancer Research |
Method for treating pancreatic cancer in humans with water-insoluble S-camptothecin of the closed lactone ring form and derivatives thereof
|
HUT70952A
(en)
*
|
1992-06-10 |
1995-11-28 |
Eastman Kodak Co |
Surface modified nanoparticles based on nosteroidal inflammatory drugs, process for preparing them and pharmaceutical compns. contg. them
|
US5552156A
(en)
*
|
1992-10-23 |
1996-09-03 |
Ohio State University |
Liposomal and micellular stabilization of camptothecin drugs
|
NZ248813A
(en)
*
|
1992-11-25 |
1995-06-27 |
Eastman Kodak Co |
Polymeric grinding media used in grinding pharmaceutical substances
|
US5346702A
(en)
*
|
1992-12-04 |
1994-09-13 |
Sterling Winthrop Inc. |
Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
|
US5298262A
(en)
*
|
1992-12-04 |
1994-03-29 |
Sterling Winthrop Inc. |
Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
|
US5302401A
(en)
*
|
1992-12-09 |
1994-04-12 |
Sterling Winthrop Inc. |
Method to reduce particle size growth during lyophilization
|
US5340564A
(en)
*
|
1992-12-10 |
1994-08-23 |
Sterling Winthrop Inc. |
Formulations comprising olin 10-G to prevent particle aggregation and increase stability
|
US5336507A
(en)
*
|
1992-12-11 |
1994-08-09 |
Sterling Winthrop Inc. |
Use of charged phospholipids to reduce nanoparticle aggregation
|
US5429824A
(en)
*
|
1992-12-15 |
1995-07-04 |
Eastman Kodak Company |
Use of tyloxapole as a nanoparticle stabilizer and dispersant
|
US5256328A
(en)
*
|
1992-12-16 |
1993-10-26 |
Eastman Kodak Company |
Liquid toilet bowl cleaner and sanitizer containing halogen donating nanoparticles
|
US5364550A
(en)
*
|
1992-12-16 |
1994-11-15 |
Eastman Kodak Company |
Liquid detergent composition
|
US5322679A
(en)
*
|
1992-12-16 |
1994-06-21 |
Sterling Winthrop Inc. |
Iodinated aroyloxy esters
|
US5352459A
(en)
*
|
1992-12-16 |
1994-10-04 |
Sterling Winthrop Inc. |
Use of purified surface modifiers to prevent particle aggregation during sterilization
|
US5326552A
(en)
*
|
1992-12-17 |
1994-07-05 |
Sterling Winthrop Inc. |
Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants
|
US5354564A
(en)
*
|
1992-12-18 |
1994-10-11 |
Eastman Kodak Company |
Personal care compositions
|
US6491938B2
(en)
|
1993-05-13 |
2002-12-10 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5981568A
(en)
*
|
1993-01-28 |
1999-11-09 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US6663881B2
(en)
|
1993-01-28 |
2003-12-16 |
Neorx Corporation |
Therapeutic inhibitor of vascular smooth muscle cells
|
US5916596A
(en)
*
|
1993-02-22 |
1999-06-29 |
Vivorx Pharmaceuticals, Inc. |
Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
|
US6537579B1
(en)
|
1993-02-22 |
2003-03-25 |
American Bioscience, Inc. |
Compositions and methods for administration of pharmacologically active compounds
|
FR2702160B1
(fr)
*
|
1993-03-02 |
1995-06-02 |
Biovecteurs As |
Vecteurs particulaires synthétiques et procédé de préparation.
|
US5849263A
(en)
*
|
1993-03-30 |
1998-12-15 |
Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
|
US5840277A
(en)
*
|
1993-03-30 |
1998-11-24 |
Charlotte Hospital Authority |
Treatment of chronic pulmonary inflammation
|
US5830436A
(en)
*
|
1993-03-30 |
1998-11-03 |
Duke University |
Method of mucociliary clearance in cystic fibrosis patients using alkylaryl polyether alcohol polymers
|
CH686761A5
(de)
|
1993-05-27 |
1996-06-28 |
Sandoz Ag |
Galenische Formulierungen.
|
US5543158A
(en)
*
|
1993-07-23 |
1996-08-06 |
Massachusetts Institute Of Technology |
Biodegradable injectable nanoparticles
|
US5635206A
(en)
*
|
1994-01-20 |
1997-06-03 |
Hoffmann-La Roche Inc. |
Process for liposomes or proliposomes
|
US5468598A
(en)
*
|
1994-04-18 |
1995-11-21 |
Eastman Kodak Company |
Solid particle dispersions for imaging systems
|
EP0678771B1
(en)
*
|
1994-04-18 |
2001-11-21 |
Eastman Kodak Company |
Stable aqueous solid particle dispersions
|
US5500331A
(en)
*
|
1994-05-25 |
1996-03-19 |
Eastman Kodak Company |
Comminution with small particle milling media
|
TW384224B
(en)
*
|
1994-05-25 |
2000-03-11 |
Nano Sys Llc |
Method of preparing submicron particles of a therapeutic or diagnostic agent
|
US5478705A
(en)
*
|
1994-05-25 |
1995-12-26 |
Eastman Kodak Company |
Milling a compound useful in imaging elements using polymeric milling media
|
US5513803A
(en)
*
|
1994-05-25 |
1996-05-07 |
Eastman Kodak Company |
Continuous media recirculation milling process
|
US5587143A
(en)
*
|
1994-06-28 |
1996-12-24 |
Nanosystems L.L.C. |
Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
|
US6007845A
(en)
*
|
1994-07-22 |
1999-12-28 |
Massachusetts Institute Of Technology |
Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
|
US5626862A
(en)
*
|
1994-08-02 |
1997-05-06 |
Massachusetts Institute Of Technology |
Controlled local delivery of chemotherapeutic agents for treating solid tumors
|
US20110196039A9
(en)
*
|
1994-10-05 |
2011-08-11 |
Kaesemeyer Wayne H |
Controlled release arginine formulations
|
DE4440337A1
(de)
*
|
1994-11-11 |
1996-05-15 |
Dds Drug Delivery Services Ges |
Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
|
US5955108A
(en)
*
|
1994-12-16 |
1999-09-21 |
Quadrant Healthcare (Uk) Limited |
Cross-linked microparticles and their use as therapeutic vehicles
|
US6524557B1
(en)
*
|
1994-12-22 |
2003-02-25 |
Astrazeneca Ab |
Aerosol formulations of peptides and proteins
|
US5609998A
(en)
*
|
1994-12-29 |
1997-03-11 |
Eastman Kodak Company |
Process for dispersing concentrated aqueous slurries
|
US5628981A
(en)
*
|
1994-12-30 |
1997-05-13 |
Nano Systems L.L.C. |
Formulations of oral gastrointestinal diagnostic x-ray contrast agents and oral gastrointestinal therapeutic agents
|
US5585108A
(en)
*
|
1994-12-30 |
1996-12-17 |
Nanosystems L.L.C. |
Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
|
US20020048596A1
(en)
*
|
1994-12-30 |
2002-04-25 |
Gregor Cevc |
Preparation for the transport of an active substance across barriers
|
US5466440A
(en)
*
|
1994-12-30 |
1995-11-14 |
Eastman Kodak Company |
Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays
|
US5716642A
(en)
*
|
1995-01-10 |
1998-02-10 |
Nano Systems L.L.C. |
Microprecipitation of nanoparticulate pharmaceutical agents using surface active material derived from similar pharmaceutical agents
|
US5665331A
(en)
*
|
1995-01-10 |
1997-09-09 |
Nanosystems L.L.C. |
Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
|
US5662883A
(en)
*
|
1995-01-10 |
1997-09-02 |
Nanosystems L.L.C. |
Microprecipitation of micro-nanoparticulate pharmaceutical agents
|
US5560932A
(en)
*
|
1995-01-10 |
1996-10-01 |
Nano Systems L.L.C. |
Microprecipitation of nanoparticulate pharmaceutical agents
|
US5569448A
(en)
*
|
1995-01-24 |
1996-10-29 |
Nano Systems L.L.C. |
Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
|
US5520904A
(en)
*
|
1995-01-27 |
1996-05-28 |
Mallinckrodt Medical, Inc. |
Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging
|
EP0808154B1
(en)
*
|
1995-02-06 |
2000-12-20 |
Elan Pharma International Limited |
Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
|
US5571536A
(en)
*
|
1995-02-06 |
1996-11-05 |
Nano Systems L.L.C. |
Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
|
US5503723A
(en)
*
|
1995-02-08 |
1996-04-02 |
Eastman Kodak Company |
Isolation of ultra small particles
|
US5665330A
(en)
*
|
1995-02-08 |
1997-09-09 |
Nano Systems Llc |
Dual purposed diagnostic/therapeutic agent having a tri-iodinated benzoyl group linked to a coumarin
|
US5518738A
(en)
*
|
1995-02-09 |
1996-05-21 |
Nanosystem L.L.C. |
Nanoparticulate nsaid compositions
|
US5622938A
(en)
*
|
1995-02-09 |
1997-04-22 |
Nano Systems L.L.C. |
Sugar base surfactant for nanocrystals
|
US5591456A
(en)
*
|
1995-02-10 |
1997-01-07 |
Nanosystems L.L.C. |
Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
|
US5573783A
(en)
*
|
1995-02-13 |
1996-11-12 |
Nano Systems L.L.C. |
Redispersible nanoparticulate film matrices with protective overcoats
|
US5510118A
(en)
*
|
1995-02-14 |
1996-04-23 |
Nanosystems Llc |
Process for preparing therapeutic compositions containing nanoparticles
|
US5543133A
(en)
*
|
1995-02-14 |
1996-08-06 |
Nanosystems L.L.C. |
Process of preparing x-ray contrast compositions containing nanoparticles
|
WO1996025181A1
(en)
*
|
1995-02-14 |
1996-08-22 |
Nanosystems L.L.C. |
Process of preparing lymphography contrast agents
|
US5580579A
(en)
*
|
1995-02-15 |
1996-12-03 |
Nano Systems L.L.C. |
Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
|
CA2213638C
(en)
*
|
1995-02-24 |
2004-05-04 |
Nanosystems L.L.C. |
Aerosols containing nanoparticle dispersions
|
US5565188A
(en)
*
|
1995-02-24 |
1996-10-15 |
Nanosystems L.L.C. |
Polyalkylene block copolymers as surface modifiers for nanoparticles
|
US5747001A
(en)
*
|
1995-02-24 |
1998-05-05 |
Nanosystems, L.L.C. |
Aerosols containing beclomethazone nanoparticle dispersions
|
US5736156A
(en)
*
|
1995-03-22 |
1998-04-07 |
The Ohio State University |
Liposomal anf micellular stabilization of camptothecin drugs
|
US5605696A
(en)
*
|
1995-03-30 |
1997-02-25 |
Advanced Cardiovascular Systems, Inc. |
Drug loaded polymeric material and method of manufacture
|
US6428771B1
(en)
*
|
1995-05-15 |
2002-08-06 |
Pharmaceutical Discovery Corporation |
Method for drug delivery to the pulmonary system
|
IL118088A0
(en)
*
|
1995-06-07 |
1996-08-04 |
Anzon Inc |
Colloidal particles of solid flame retardant and smoke suppressant compounds and methods for making them
|
DE69526787T2
(de)
*
|
1995-07-05 |
2002-12-05 |
Europ Community Luxemburg Luxe |
Biokompatibele und biodegradierbare Nanokapseln zur Absorption und Verabreichung von proteinischen Arzneimitteln
|
BE1009856A5
(fr)
*
|
1995-07-14 |
1997-10-07 |
Sandoz Sa |
Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule.
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
US6391338B1
(en)
*
|
1995-09-07 |
2002-05-21 |
Biovail Technologies Ltd. |
System for rendering substantially non-dissoluble bio-affecting agents bio-available
|
US5834025A
(en)
|
1995-09-29 |
1998-11-10 |
Nanosystems L.L.C. |
Reduction of intravenously administered nanoparticulate-formulation-induced adverse physiological reactions
|
DE69637441T2
(de)
*
|
1995-10-17 |
2009-03-05 |
Jagotec Ag |
Verabreichung unlöslicher arzneistoffe
|
US5679138A
(en)
*
|
1995-11-30 |
1997-10-21 |
Eastman Kodak Company |
Ink jet inks containing nanoparticles of organic pigments
|
US5662279A
(en)
*
|
1995-12-05 |
1997-09-02 |
Eastman Kodak Company |
Process for milling and media separation
|
US20050267302A1
(en)
*
|
1995-12-11 |
2005-12-01 |
G.D. Searle & Co. |
Eplerenone crystalline form exhibiting enhanced dissolution rate
|
US5968543A
(en)
*
|
1996-01-05 |
1999-10-19 |
Advanced Polymer Systems, Inc. |
Polymers with controlled physical state and bioerodibility
|
US5686133A
(en)
*
|
1996-01-31 |
1997-11-11 |
Port Systems, L.L.C. |
Water soluble pharmaceutical coating and method for producing coated pharmaceuticals
|
US5611344A
(en)
*
|
1996-03-05 |
1997-03-18 |
Acusphere, Inc. |
Microencapsulated fluorinated gases for use as imaging agents
|
DE69729088T2
(de)
*
|
1996-03-05 |
2005-05-12 |
Acusphere, Inc., Cambridge |
Mikroverkapselte fluorierte gase zur anwendung als bilderzeugende mittel
|
JP4024302B2
(ja)
*
|
1996-05-17 |
2007-12-19 |
クアドラント、 ドラッグ、 デリバリー、 リミテッド |
微粒子および創傷治療におけるその用途
|
USRE37053E1
(en)
|
1996-05-24 |
2001-02-13 |
Massachusetts Institute Of Technology |
Particles incorporating surfactants for pulmonary drug delivery
|
KR20040097250A
(ko)
|
1996-05-24 |
2004-11-17 |
유니버시티 오브 브리티시 콜롬비아 |
신체 통로의 질병을 치료 또는 예방하기 위한 조성물 및방법
|
US6652837B1
(en)
*
|
1996-05-24 |
2003-11-25 |
Massachusetts Institute Of Technology |
Preparation of novel particles for inhalation
|
US5874064A
(en)
|
1996-05-24 |
1999-02-23 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US20020052310A1
(en)
*
|
1997-09-15 |
2002-05-02 |
Massachusetts Institute Of Technology The Penn State Research Foundation |
Particles for inhalation having sustained release properties
|
US6254854B1
(en)
*
|
1996-05-24 |
2001-07-03 |
The Penn Research Foundation |
Porous particles for deep lung delivery
|
US6503480B1
(en)
*
|
1997-05-23 |
2003-01-07 |
Massachusetts Institute Of Technology |
Aerodynamically light particles for pulmonary drug delivery
|
US5726154A
(en)
*
|
1996-06-28 |
1998-03-10 |
University Of Utah Research Foundation |
Stabilization and oral delivery of calcitonin
|
US5837221A
(en)
*
|
1996-07-29 |
1998-11-17 |
Acusphere, Inc. |
Polymer-lipid microencapsulated gases for use as imaging agents
|
US5935890A
(en)
|
1996-08-01 |
1999-08-10 |
Glcc Technologies, Inc. |
Stable dispersions of metal passivation agents and methods for making them
|
US6465016B2
(en)
|
1996-08-22 |
2002-10-15 |
Research Triangle Pharmaceuticals |
Cyclosporiine particles
|
US7255877B2
(en)
*
|
1996-08-22 |
2007-08-14 |
Jagotec Ag |
Fenofibrate microparticles
|
US7060253B1
(en)
*
|
1996-09-20 |
2006-06-13 |
Mundschenk David D |
Topical formulations and delivery systems
|
GB9622173D0
(en)
*
|
1996-10-24 |
1996-12-18 |
Glaxo Group Ltd |
Particulate Products
|
US6515016B2
(en)
|
1996-12-02 |
2003-02-04 |
Angiotech Pharmaceuticals, Inc. |
Composition and methods of paclitaxel for treating psoriasis
|
FR2758459B1
(fr)
*
|
1997-01-17 |
1999-05-07 |
Pharma Pass |
Composition pharmaceutique de fenofibrate presentant une biodisponibilite elevee et son procede de preparation
|
US5993856A
(en)
*
|
1997-01-24 |
1999-11-30 |
Femmepharma |
Pharmaceutical preparations and methods for their administration
|
US6416778B1
(en)
|
1997-01-24 |
2002-07-09 |
Femmepharma |
Pharmaceutical preparations and methods for their regional administration
|
WO1998035666A1
(en)
*
|
1997-02-13 |
1998-08-20 |
Nanosystems Llc |
Formulations of nanoparticle naproxen tablets
|
US6045829A
(en)
*
|
1997-02-13 |
2000-04-04 |
Elan Pharma International Limited |
Nanocrystalline formulations of human immunodeficiency virus (HIV) protease inhibitors using cellulosic surface stabilizers
|
CO4920215A1
(es)
*
|
1997-02-14 |
2000-05-29 |
Novartis Ag |
Tabletas de oxacarbazepina recubiertas de una pelicula y metodo para la produccion de estas formulaciones
|
US20050004049A1
(en)
*
|
1997-03-11 |
2005-01-06 |
Elan Pharma International Limited |
Novel griseofulvin compositions
|
US5989591A
(en)
*
|
1997-03-14 |
1999-11-23 |
American Home Products Corporation |
Rapamycin formulations for oral administration
|
US6193954B1
(en)
*
|
1997-03-21 |
2001-02-27 |
Abbott Laboratories |
Formulations for pulmonary delivery of dopamine agonists
|
AU7133898A
(en)
*
|
1997-04-18 |
1998-11-13 |
Vertex Pharmaceuticals Incorporated |
Nanosized aspartyl protease inhibitors
|
ATE221887T1
(de)
|
1997-05-08 |
2002-08-15 |
Merck Sharp & Dohme |
Substituierte 1,2,4-triazolo(3,4,-a)phthalazin- derivate als gaba-alpha 5-liganden
|
IT1292142B1
(it)
*
|
1997-06-12 |
1999-01-25 |
Maria Rosa Gasco |
Composizione farmaceutica in forma di microparticelle lipidiche solide atte alla somministrazione parenterale
|
AU8145198A
(en)
*
|
1997-06-16 |
1999-01-04 |
Vertex Pharmaceuticals Incorporated |
Methods of increasing the bioavailability of stable crystal polymorphs of a compound
|
EP2272504A3
(en)
|
1997-06-27 |
2014-02-26 |
Abraxis BioScience, LLC |
Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
|
PT1023050E
(pt)
*
|
1997-06-27 |
2013-12-04 |
Abraxis Bioscience Llc |
Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização
|
US7052678B2
(en)
|
1997-09-15 |
2006-05-30 |
Massachusetts Institute Of Technology |
Particles for inhalation having sustained release properties
|
US6309623B1
(en)
|
1997-09-29 |
2001-10-30 |
Inhale Therapeutic Systems, Inc. |
Stabilized preparations for use in metered dose inhalers
|
US6946117B1
(en)
*
|
1997-09-29 |
2005-09-20 |
Nektar Therapeutics |
Stabilized preparations for use in nebulizers
|
US20020017295A1
(en)
*
|
2000-07-07 |
2002-02-14 |
Weers Jeffry G. |
Phospholipid-based powders for inhalation
|
US6565885B1
(en)
*
|
1997-09-29 |
2003-05-20 |
Inhale Therapeutic Systems, Inc. |
Methods of spray drying pharmaceutical compositions
|
US20060165606A1
(en)
|
1997-09-29 |
2006-07-27 |
Nektar Therapeutics |
Pulmonary delivery particles comprising water insoluble or crystalline active agents
|
US6919070B1
(en)
*
|
1997-10-17 |
2005-07-19 |
Zakrytoe Aktsionernoe Obschestvo “OSTIM” |
Stomatic composition
|
UA72189C2
(uk)
|
1997-11-17 |
2005-02-15 |
Янссен Фармацевтика Н.В. |
Фармацевтична композиція, що містить водну суспензію субмікронних ефірів 9-гідроксирисперидон жирних кислот
|
GB9726543D0
(en)
*
|
1997-12-16 |
1998-02-11 |
Smithkline Beecham Plc |
Novel compositions
|
US6086376A
(en)
*
|
1998-01-30 |
2000-07-11 |
Rtp Pharma Inc. |
Dry aerosol suspension of phospholipid-stabilized drug microparticles in a hydrofluoroalkane propellant
|
KR20010041234A
(ko)
|
1998-02-25 |
2001-05-15 |
더블유. 지. 콜 |
치환된 1,2,4-트리아졸로[3,4-a]피리다진
|
ZA991922B
(en)
*
|
1998-03-11 |
1999-09-13 |
Smithkline Beecham Corp |
Novel compositions of eprosartan.
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
US6337092B1
(en)
|
1998-03-30 |
2002-01-08 |
Rtp Pharma Inc. |
Composition and method of preparing microparticles of water-insoluble substances
|
AU761205B2
(en)
*
|
1998-03-30 |
2003-05-29 |
Skyepharma Canada Inc. |
Composition and method of preparing microparticles of water-insoluble substances
|
US6979456B1
(en)
|
1998-04-01 |
2005-12-27 |
Jagotec Ag |
Anticancer compositions
|
AU764001B2
(en)
|
1998-05-29 |
2003-08-07 |
Skyepharma Canada Inc. |
Thermoprotected microparticle compositions and process for terminal steam sterilization thereof
|
US6153225A
(en)
*
|
1998-08-13 |
2000-11-28 |
Elan Pharma International Limited |
Injectable formulations of nanoparticulate naproxen
|
US6956021B1
(en)
*
|
1998-08-25 |
2005-10-18 |
Advanced Inhalation Research, Inc. |
Stable spray-dried protein formulations
|
US6165506A
(en)
*
|
1998-09-04 |
2000-12-26 |
Elan Pharma International Ltd. |
Solid dose form of nanoparticulate naproxen
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
AU6283299A
(en)
*
|
1998-10-01 |
2000-04-17 |
Elan Pharma International Limited |
Controlled release nanoparticulate compositions
|
US8293277B2
(en)
*
|
1998-10-01 |
2012-10-23 |
Alkermes Pharma Ireland Limited |
Controlled-release nanoparticulate compositions
|
US20040013613A1
(en)
*
|
2001-05-18 |
2004-01-22 |
Jain Rajeev A |
Rapidly disintegrating solid oral dosage form
|
US8236352B2
(en)
*
|
1998-10-01 |
2012-08-07 |
Alkermes Pharma Ireland Limited |
Glipizide compositions
|
US20080213378A1
(en)
*
|
1998-10-01 |
2008-09-04 |
Elan Pharma International, Ltd. |
Nanoparticulate statin formulations and novel statin combinations
|
US20090297602A1
(en)
*
|
1998-11-02 |
2009-12-03 |
Devane John G |
Modified Release Loxoprofen Compositions
|
US20070160675A1
(en)
*
|
1998-11-02 |
2007-07-12 |
Elan Corporation, Plc |
Nanoparticulate and controlled release compositions comprising a cephalosporin
|
DK1126826T6
(en)
*
|
1998-11-02 |
2019-06-24 |
Alkermes Pharma Ireland Ltd |
Multiparticulate modified release of methylphenidate
|
US6428814B1
(en)
*
|
1999-10-08 |
2002-08-06 |
Elan Pharma International Ltd. |
Bioadhesive nanoparticulate compositions having cationic surface stabilizers
|
US6375986B1
(en)
|
2000-09-21 |
2002-04-23 |
Elan Pharma International Ltd. |
Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate
|
US6969529B2
(en)
*
|
2000-09-21 |
2005-11-29 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers
|
GB9824897D0
(en)
|
1998-11-12 |
1999-01-06 |
Merck Sharp & Dohme |
Therapeutic compounds
|
EP1131070B1
(en)
*
|
1998-11-12 |
2008-09-03 |
SmithKline Beecham plc |
Pharmaceutical composition for modified release of an insulin sensitiser and metformin
|
US7521068B2
(en)
|
1998-11-12 |
2009-04-21 |
Elan Pharma International Ltd. |
Dry powder aerosols of nanoparticulate drugs
|
ID29270A
(id)
|
1998-11-20 |
2001-08-16 |
Rtp Pharma Inc |
Partikel-partikel mikro yang distabilkan oleh fosfolipid yang dapat menyebar
|
US20040009535A1
(en)
|
1998-11-27 |
2004-01-15 |
Celltech R&D, Inc. |
Compositions and methods for increasing bone mineralization
|
DK2261335T3
(en)
|
1998-11-27 |
2017-09-18 |
Ucb Pharma Sa |
Compositions and Methods for Increasing Bone Mineralization
|
DE19856432A1
(de)
*
|
1998-12-08 |
2000-06-15 |
Basf Ag |
Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
|
ES2173679T3
(es)
|
1999-01-27 |
2002-10-16 |
Idea Ag |
Inmunizacion/transporte transnasal con vehiculos altamente adaptables.
|
EP1031346B1
(en)
|
1999-01-27 |
2002-05-02 |
Idea Ag |
Noninvasive vaccination through the skin
|
US6294192B1
(en)
|
1999-02-26 |
2001-09-25 |
Lipocine, Inc. |
Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
|
US6761903B2
(en)
|
1999-06-30 |
2004-07-13 |
Lipocine, Inc. |
Clear oil-containing pharmaceutical compositions containing a therapeutic agent
|
US7374779B2
(en)
*
|
1999-02-26 |
2008-05-20 |
Lipocine, Inc. |
Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
|
US6267985B1
(en)
*
|
1999-06-30 |
2001-07-31 |
Lipocine Inc. |
Clear oil-containing pharmaceutical compositions
|
US6270806B1
(en)
|
1999-03-03 |
2001-08-07 |
Elan Pharma International Limited |
Use of peg-derivatized lipids as surface stabilizers for nanoparticulate compositions
|
US6267989B1
(en)
*
|
1999-03-08 |
2001-07-31 |
Klan Pharma International Ltd. |
Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
|
EG23951A
(en)
|
1999-03-25 |
2008-01-29 |
Otsuka Pharma Co Ltd |
Cilostazol preparation
|
US6383471B1
(en)
|
1999-04-06 |
2002-05-07 |
Lipocine, Inc. |
Compositions and methods for improved delivery of ionizable hydrophobic therapeutic agents
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
AU4225700A
(en)
*
|
1999-04-12 |
2000-11-14 |
Dow Agrosciences Llc |
Aqueous dispersions of agricultural chemicals
|
US6491239B2
(en)
|
1999-05-06 |
2002-12-10 |
Eastman Kodak Company |
Process for milling compounds
|
US6309749B1
(en)
|
1999-05-06 |
2001-10-30 |
Eastman Kodak Company |
Ceramic milling media containing tetragonal zirconia
|
US6444223B1
(en)
*
|
1999-05-28 |
2002-09-03 |
Alkermes Controlled Therapeutics, Inc. |
Method of producing submicron particles of a labile agent and use thereof
|
AU5300000A
(en)
*
|
1999-06-01 |
2000-12-18 |
Elan Pharma International Limited |
Small-scale mill and method thereof
|
US20040115134A1
(en)
*
|
1999-06-22 |
2004-06-17 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US20090104273A1
(en)
*
|
1999-06-22 |
2009-04-23 |
Elan Pharma International Ltd. |
Novel nifedipine compositions
|
US6555139B2
(en)
|
1999-06-28 |
2003-04-29 |
Wockhardt Europe Limited |
Preparation of micron-size pharmaceutical particles by microfluidization
|
US9006175B2
(en)
|
1999-06-29 |
2015-04-14 |
Mannkind Corporation |
Potentiation of glucose elimination
|
ATE545652T1
(de)
*
|
1999-06-29 |
2012-03-15 |
Mannkind Corp |
Reinigung und stabilisierung von proteinen und peptiden in pharmaceutischen agentien
|
US6309663B1
(en)
|
1999-08-17 |
2001-10-30 |
Lipocine Inc. |
Triglyceride-free compositions and methods for enhanced absorption of hydrophilic therapeutic agents
|
US6458383B2
(en)
|
1999-08-17 |
2002-10-01 |
Lipocine, Inc. |
Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin
|
US6982281B1
(en)
*
|
2000-11-17 |
2006-01-03 |
Lipocine Inc |
Pharmaceutical compositions and dosage forms for administration of hydrophobic drugs
|
MXPA02000053A
(es)
*
|
1999-07-05 |
2003-07-21 |
Idea Ag |
Un metodo para mejorar el tratamiento a traves de barreras adaptables semipermeables.
|
US6576224B1
(en)
*
|
1999-07-06 |
2003-06-10 |
Sinuspharma, Inc. |
Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
|
FR2795961B1
(fr)
*
|
1999-07-09 |
2004-05-28 |
Ethypharm Lab Prod Ethiques |
Composition pharmaceutique contenant du fenofibrate micronise, un tensioactif et un derive cellulosique liant et procede de preparation
|
US7863331B2
(en)
|
1999-07-09 |
2011-01-04 |
Ethypharm |
Pharmaceutical composition containing fenofibrate and method for the preparation thereof
|
IL147828A0
(en)
|
1999-08-12 |
2002-08-14 |
Lilly Co Eli |
Oral treatment of companion animals with ectoparasiticidal spinosyns
|
US6927210B1
(en)
|
1999-08-12 |
2005-08-09 |
Eli Lilly And Company |
Ectoparasiticidal aqueous suspension formulations of spinosyns
|
US6933318B1
(en)
|
1999-08-12 |
2005-08-23 |
Eli Lilly And Company |
Topical organic ectoparasiticidal formulations
|
US6749835B1
(en)
|
1999-08-25 |
2004-06-15 |
Advanced Inhalation Research, Inc. |
Formulation for spray-drying large porous particles
|
US20010036481A1
(en)
*
|
1999-08-25 |
2001-11-01 |
Advanced Inhalation Research, Inc. |
Modulation of release from dry powder formulations
|
JP2003507410A
(ja)
*
|
1999-08-25 |
2003-02-25 |
アドバンスト インハレーション リサーチ,インコーポレイテッド |
乾燥粉末製剤からの放出調節
|
US7678364B2
(en)
|
1999-08-25 |
2010-03-16 |
Alkermes, Inc. |
Particles for inhalation having sustained release properties
|
US6656504B1
(en)
|
1999-09-09 |
2003-12-02 |
Elan Pharma International Ltd. |
Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
|
CA2386841A1
(en)
*
|
1999-10-07 |
2001-04-12 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
EP2295043A1
(en)
|
1999-10-29 |
2011-03-16 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
US10179130B2
(en)
|
1999-10-29 |
2019-01-15 |
Purdue Pharma L.P. |
Controlled release hydrocodone formulations
|
US20030203884A1
(en)
*
|
1999-11-09 |
2003-10-30 |
Pharmacia Corporation |
Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
|
US20030096798A1
(en)
*
|
1999-11-09 |
2003-05-22 |
Williams Gordon H. |
Methods for the treatment or prophylaxis of aldosterone-mediated pathogenic effects in a subject using an epoxy-steroidal aldosterone antagonist
|
AUPQ441699A0
(en)
|
1999-12-02 |
2000-01-06 |
Eli Lilly And Company |
Pour-on formulations
|
US6251136B1
(en)
|
1999-12-08 |
2001-06-26 |
Advanced Cardiovascular Systems, Inc. |
Method of layering a three-coated stent using pharmacological and polymeric agents
|
UA74539C2
(en)
|
1999-12-08 |
2006-01-16 |
Pharmacia Corp |
Crystalline polymorphous forms of celecoxib (variants), a method for the preparation thereof (variants), a pharmaceutical composition (variants)
|
US20030083493A1
(en)
*
|
1999-12-08 |
2003-05-01 |
Barton Kathleen P. |
Eplerenone drug substance having high phase purity
|
KR100793668B1
(ko)
*
|
1999-12-08 |
2008-01-10 |
파마시아 코포레이션 |
강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
|
BR0008054A
(pt)
*
|
1999-12-08 |
2002-03-12 |
Pharmacia Corp |
Forma cristalina de eplerenona
|
US6702849B1
(en)
|
1999-12-13 |
2004-03-09 |
Advanced Cardiovascular Systems, Inc. |
Method of processing open-celled microcellular polymeric foams with controlled porosity for use as vascular grafts and stent covers
|
JP2003518038A
(ja)
|
1999-12-20 |
2003-06-03 |
ニコラス, ジェイ カークホフ, |
流動床噴霧乾燥によるナノ粒子製造方法
|
US8771740B2
(en)
*
|
1999-12-20 |
2014-07-08 |
Nicholas J. Kerkhof |
Process for producing nanoparticles by spray drying
|
GB9930562D0
(en)
*
|
1999-12-23 |
2000-02-16 |
Boc Group Plc |
Partial oxidation of hydrogen sulphide
|
MXPA02006324A
(es)
|
1999-12-23 |
2002-12-13 |
Pfizer Prod Inc |
Composiciones farmaceuticas que proporcionan concentraciones potenciadas de farmaco.
|
US7732404B2
(en)
|
1999-12-30 |
2010-06-08 |
Dexcel Ltd |
Pro-nanodispersion for the delivery of cyclosporin
|
DE60119693T2
(de)
*
|
2000-01-31 |
2007-04-26 |
Engelhard Corp. |
Tensidfreie topische zusammensetzungen und verfahren zur schnellen herstellung davon
|
CA2400842C
(en)
|
2000-02-23 |
2013-01-15 |
Smithkline Beecham Biologicals S.A. |
Novel compounds
|
AU2001241738A1
(en)
*
|
2000-02-25 |
2001-09-03 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
CA2400172C
(en)
*
|
2000-02-28 |
2010-04-20 |
Genesegues, Inc. |
Nanocapsule encapsulation system and method
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
AUPQ634300A0
(en)
*
|
2000-03-20 |
2000-04-15 |
Eli Lilly And Company |
Synergistic formulations
|
US7153525B1
(en)
*
|
2000-03-22 |
2006-12-26 |
The University Of Kentucky Research Foundation |
Microemulsions as precursors to solid nanoparticles
|
US6992081B2
(en)
|
2000-03-23 |
2006-01-31 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
US7119085B2
(en)
|
2000-03-23 |
2006-10-10 |
Elan Pharmaceuticals, Inc. |
Methods to treat alzheimer's disease
|
GB0009773D0
(en)
*
|
2000-04-19 |
2000-06-07 |
Univ Cardiff |
Particulate composition
|
NZ522239A
(en)
|
2000-04-20 |
2004-03-26 |
Skyepharma Canada Inc |
Improved water-insoluble drug particle process
|
US8404217B2
(en)
|
2000-05-10 |
2013-03-26 |
Novartis Ag |
Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
|
ES2303527T3
(es)
|
2000-05-10 |
2008-08-16 |
Jagotec Ag |
Procedimiento de molienda.
|
US7871598B1
(en)
|
2000-05-10 |
2011-01-18 |
Novartis Ag |
Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
|
EP1280520B2
(en)
|
2000-05-10 |
2018-03-21 |
Novartis AG |
Phospholipid-based powders for drug delivery
|
US6316029B1
(en)
*
|
2000-05-18 |
2001-11-13 |
Flak Pharma International, Ltd. |
Rapidly disintegrating solid oral dosage form
|
US20040156872A1
(en)
*
|
2000-05-18 |
2004-08-12 |
Elan Pharma International Ltd. |
Novel nimesulide compositions
|
MY120279A
(en)
|
2000-05-26 |
2005-09-30 |
Pharmacia Corp |
Use of a celecoxib composition for fast pain relief
|
AU6867801A
(en)
*
|
2000-06-20 |
2002-01-02 |
Corixa Corp |
Fusion proteins of mycobacterium tuberculosis
|
KR20030011371A
(ko)
*
|
2000-06-27 |
2003-02-07 |
진랩스 테크놀러지스, 인크. |
항세균, 항진균 또는 항암 활성을 갖는 신규 화합물
|
JP2004513615A
(ja)
|
2000-06-28 |
2004-05-13 |
コリクサ コーポレイション |
肺癌の治療および診断のための組成物および方法
|
EP1666452A2
(en)
|
2000-06-30 |
2006-06-07 |
Elan Pharmaceuticals, Inc. |
Compounds to treat Alzheimer's disease
|
NZ523005A
(en)
*
|
2000-06-30 |
2004-11-26 |
Elan Pharm Inc |
Compounds to treat alzheimer's disease
|
US6846813B2
(en)
|
2000-06-30 |
2005-01-25 |
Pharmacia & Upjohn Company |
Compounds to treat alzheimer's disease
|
PE20020276A1
(es)
|
2000-06-30 |
2002-04-06 |
Elan Pharm Inc |
COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
|
US20030096864A1
(en)
*
|
2000-06-30 |
2003-05-22 |
Fang Lawrence Y. |
Compounds to treat alzheimer's disease
|
IN192160B
(ja)
*
|
2000-07-17 |
2004-02-28 |
Ranbaxy Lab |
|
US6656505B2
(en)
*
|
2000-07-21 |
2003-12-02 |
Alpharma Uspd Inc. |
Method for forming an aqueous flocculated suspension
|
US6716829B2
(en)
|
2000-07-27 |
2004-04-06 |
Pharmacia Corporation |
Aldosterone antagonist and cyclooxygenase-2 inhibitor combination therapy to prevent or treat inflammation-related cardiovascular disorders
|
JP2004511435A
(ja)
*
|
2000-07-27 |
2004-04-15 |
ファルマシア・コーポレーション |
うっ血性心不全の処置のための、エポキシ−ステロイド型アルドステロン拮抗薬とβ−アドレナリン作動性拮抗薬の併用療法
|
CA2419256A1
(en)
*
|
2000-08-28 |
2002-03-07 |
Kenton N. Fedde |
Use of an aldosterone receptor antagonist to improve cognitive function
|
WO2002017883A2
(en)
|
2000-08-31 |
2002-03-07 |
Rtp Pharma Inc. |
Milled particles
|
US8586094B2
(en)
|
2000-09-20 |
2013-11-19 |
Jagotec Ag |
Coated tablets
|
US7998507B2
(en)
*
|
2000-09-21 |
2011-08-16 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors
|
US20030224058A1
(en)
|
2002-05-24 |
2003-12-04 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US7276249B2
(en)
*
|
2002-05-24 |
2007-10-02 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
US20040033267A1
(en)
*
|
2002-03-20 |
2004-02-19 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
US7198795B2
(en)
*
|
2000-09-21 |
2007-04-03 |
Elan Pharma International Ltd. |
In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
|
US20080241070A1
(en)
*
|
2000-09-21 |
2008-10-02 |
Elan Pharma International Ltd. |
Fenofibrate dosage forms
|
EP2932964A1
(en)
|
2000-10-30 |
2015-10-21 |
Euro-Celtique S.A. |
Controlled release hydrocodone formulations
|
US6756062B2
(en)
|
2000-11-03 |
2004-06-29 |
Board Of Regents University Of Texas System |
Preparation of drug particles using evaporation precipitation into aqueous solutions
|
US8551526B2
(en)
*
|
2000-11-03 |
2013-10-08 |
Board Of Regents, The University Of Texas System |
Preparation of drug particles using evaporation precipitation into aqueous solutions
|
US20030198679A1
(en)
*
|
2000-11-08 |
2003-10-23 |
Kundu Subhas C. |
Flocculated pharmaceutical suspensions and methods for actives
|
MXPA03004095A
(es)
*
|
2000-11-09 |
2004-09-10 |
Neopharm Inc |
Complejos de sn-38 con lipidos y sus metodos de uso.
|
GB0028583D0
(en)
*
|
2000-11-23 |
2001-01-10 |
Merck Sharp & Dohme |
Therapeutic compounds
|
EP2298285A3
(en)
|
2000-11-30 |
2011-07-27 |
Vectura Limited |
Method of making particles for use in a pharmaceutical composition
|
AU2002220857A1
(en)
|
2000-11-30 |
2002-06-11 |
Vectura Limited |
Particles for use in a pharmaceutical composition
|
JP2004518642A
(ja)
*
|
2000-12-06 |
2004-06-24 |
ファルマシア・コーポレーション |
ラボラトリースケールの微粉砕化プロセス
|
KR20040025881A
(ko)
*
|
2000-12-11 |
2004-03-26 |
다케다 야쿠힌 고교 가부시키가이샤 |
개선된 흡수성을 갖는 의약 조성물
|
DE10063090A1
(de)
*
|
2000-12-18 |
2002-06-20 |
Henkel Kgaa |
Nanoskaliges ZnO in Hygiene-Produkten
|
DE10063092A1
(de)
*
|
2000-12-18 |
2002-06-20 |
Henkel Kgaa |
Nanoskalige Materialien in Hygiene-Produkten
|
US6982251B2
(en)
*
|
2000-12-20 |
2006-01-03 |
Schering Corporation |
Substituted 2-azetidinones useful as hypocholesterolemic agents
|
US9700866B2
(en)
|
2000-12-22 |
2017-07-11 |
Baxter International Inc. |
Surfactant systems for delivery of organic compounds
|
US20030096013A1
(en)
*
|
2000-12-22 |
2003-05-22 |
Jane Werling |
Preparation of submicron sized particles with polymorph control
|
US6951656B2
(en)
*
|
2000-12-22 |
2005-10-04 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
US20030072807A1
(en)
*
|
2000-12-22 |
2003-04-17 |
Wong Joseph Chung-Tak |
Solid particulate antifungal compositions for pharmaceutical use
|
US7037528B2
(en)
*
|
2000-12-22 |
2006-05-02 |
Baxter International Inc. |
Microprecipitation method for preparing submicron suspensions
|
AU2002249836B2
(en)
*
|
2000-12-22 |
2006-12-14 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
US6623761B2
(en)
|
2000-12-22 |
2003-09-23 |
Hassan Emadeldin M. |
Method of making nanoparticles of substantially water insoluble materials
|
US20040022862A1
(en)
*
|
2000-12-22 |
2004-02-05 |
Kipp James E. |
Method for preparing small particles
|
US6977085B2
(en)
*
|
2000-12-22 |
2005-12-20 |
Baxter International Inc. |
Method for preparing submicron suspensions with polymorph control
|
US7193084B2
(en)
*
|
2000-12-22 |
2007-03-20 |
Baxter International Inc. |
Polymorphic form of itraconazole
|
US20050048126A1
(en)
|
2000-12-22 |
2005-03-03 |
Barrett Rabinow |
Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
|
US8067032B2
(en)
*
|
2000-12-22 |
2011-11-29 |
Baxter International Inc. |
Method for preparing submicron particles of antineoplastic agents
|
US6884436B2
(en)
*
|
2000-12-22 |
2005-04-26 |
Baxter International Inc. |
Method for preparing submicron particle suspensions
|
US20020198254A1
(en)
*
|
2000-12-27 |
2002-12-26 |
Velligan Mark D. |
Polyamide analogs
|
US20030125236A1
(en)
*
|
2000-12-29 |
2003-07-03 |
Advenced Inhalation Research, Inc. |
Particles for inhalation having rapid release properties
|
CA2433335C
(en)
|
2000-12-29 |
2010-04-20 |
Advanced Inhalation Research, Inc. |
Particles for inhalation having sustained release properties
|
US20020141946A1
(en)
*
|
2000-12-29 |
2002-10-03 |
Advanced Inhalation Research, Inc. |
Particles for inhalation having rapid release properties
|
FI20010115A0
(fi)
*
|
2001-01-18 |
2001-01-18 |
Orion Corp |
Menetelmä nanopartikkelien valmistamiseksi
|
DE60216890T2
(de)
*
|
2001-01-26 |
2007-08-30 |
Schering Corp. |
Kombinationen von einem hemmer der sterol-absorption und einem ppar-aktivator zur behandlung von kardiovaskulären indikationen
|
US7071181B2
(en)
*
|
2001-01-26 |
2006-07-04 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
|
WO2002058731A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
|
TW200840563A
(en)
*
|
2001-01-26 |
2008-10-16 |
Schering Corp |
Combinations of nicotinic acid and derivatives thereof and sterol absorption inhibitor(S) and treatments for vascular indications
|
WO2002058733A2
(en)
*
|
2001-01-26 |
2002-08-01 |
Schering Corporation |
Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
|
US20020147184A1
(en)
*
|
2001-01-26 |
2002-10-10 |
Schering Corporation |
Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions
|
CA2434430A1
(en)
*
|
2001-01-26 |
2002-08-01 |
Harry R. Davis |
The use of substituted azetidinone compounds for the treatment of sitosterolemia
|
US20040022861A1
(en)
*
|
2001-01-30 |
2004-02-05 |
Williams Robert O. |
Process for production of nanoparticles and microparticles by spray freezing into liquid
|
CA2436418A1
(en)
*
|
2001-01-30 |
2002-08-08 |
Board Of Regents, The University Of Texas Systems |
Process for production of nanoparticles and microparticles by spray freezing into liquid
|
US20020150615A1
(en)
*
|
2001-02-12 |
2002-10-17 |
Howard Sands |
Injectable pharmaceutical composition comprising microdroplets of a camptothecin
|
US6497896B2
(en)
|
2001-02-12 |
2002-12-24 |
Supergen, Inc. |
Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
|
US6509027B2
(en)
|
2001-02-12 |
2003-01-21 |
Supergen, Inc. |
Injectable pharmaceutical composition comprising coated particles of camptothecin
|
JP3386052B2
(ja)
*
|
2001-02-13 |
2003-03-10 |
トヨタ自動車株式会社 |
ポンプ装置
|
EE05385B1
(et)
|
2001-02-14 |
2011-02-15 |
Tibotec�Pharmaceuticals�Ltd. |
LaiaspektrilisedÁ2-(asendatudÁamino)bensotiasoolsulfoonamiididÁkuiÁHIVÁproteaasiÁinhibiitorid,ÁnendeÁvalmistamismeetodÁjaÁkasutamineÁningÁfarmatseutilineÁkompositsioon
|
JP2004523552A
(ja)
*
|
2001-02-22 |
2004-08-05 |
スカイファーマ・カナダ・インコーポレーテッド |
低減した摂食−絶食効果を伴うフィブラート−スタチンの組合わせ
|
CA2443089C
(en)
*
|
2001-04-03 |
2011-11-01 |
Schering Corporation |
Antifungal suspension of micronized posaconazole
|
EP1392245A2
(en)
*
|
2001-04-05 |
2004-03-03 |
Universite Laval |
Process for making protein delivery matrix and uses thereof
|
NZ528954A
(en)
|
2001-04-09 |
2005-04-29 |
Tibotec Pharm Ltd |
Broadspectrum 2-(substituted-amino)-benzoxazole sulfonamide HIV protease inhibitors
|
US20040126900A1
(en)
*
|
2001-04-13 |
2004-07-01 |
Barry Stephen E |
High affinity peptide- containing nanoparticles
|
US6667344B2
(en)
|
2001-04-17 |
2003-12-23 |
Dey, L.P. |
Bronchodilating compositions and methods
|
US20030157161A1
(en)
*
|
2001-05-01 |
2003-08-21 |
Angiotech Pharmaceuticals, Inc. |
Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
|
US20020192280A1
(en)
*
|
2001-05-01 |
2002-12-19 |
Angiotech Pharmaceuticals, Inc. |
Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
|
ITMO20010086A1
(it)
*
|
2001-05-08 |
2002-11-08 |
Worgas Bruciatori Srl |
Metodo ed apparato per ridurre le emissioni di biossido di azoto (no2)in un apparecchio da riscaldamento senza canna fumaria
|
EP1515982A4
(en)
|
2001-05-09 |
2005-10-26 |
Corixa Corp |
METHODS AND COMPOSITIONS FOR THE THERAPY AND DIAGNOSIS OF PROSTATE CANCER
|
HUP0400438A3
(en)
|
2001-05-11 |
2007-08-28 |
Tibotec Pharm Ltd |
Broadspectrum 2-amino-benzoxazole-6-sulfonamides, their use as hiv protease inhibitor and pharmaceutical compositions containing them
|
DE10125290B4
(de)
*
|
2001-05-15 |
2005-04-14 |
Siemens Ag |
Verfahren zum Aufbereiten von Nano-Dispersanten
|
CN1533304A
(zh)
*
|
2001-05-23 |
2004-09-29 |
纳幕尔杜邦公司 |
高压介质磨
|
EP1392287B8
(en)
*
|
2001-05-25 |
2007-01-10 |
Schering Corporation |
Use of substituted azetidinone derivatives in the treatment of Alzheimer's disease
|
WO2003030864A1
(en)
*
|
2001-05-29 |
2003-04-17 |
Neopharm, Inc. |
Liposomal formulation of irinotecan
|
DE60227802D1
(de)
*
|
2001-06-05 |
2008-09-04 |
Elan Pharma Int Ltd |
Mahlvorrichtung und verfahren zu deren betrieb
|
US6976647B2
(en)
*
|
2001-06-05 |
2005-12-20 |
Elan Pharma International, Limited |
System and method for milling materials
|
US6730319B2
(en)
|
2001-06-06 |
2004-05-04 |
Hoffmann-La Roche Inc. |
Pharmaceutical compositions having depressed melting points
|
US20040173146A1
(en)
*
|
2001-06-07 |
2004-09-09 |
Figueroa Iddys D. |
Application of a bioactive agent to a delivery substrate
|
US20040173147A1
(en)
*
|
2001-06-07 |
2004-09-09 |
Figueroa Iddys D. |
Application of a bioactive agent to a delivery substrate
|
US6962715B2
(en)
*
|
2001-10-24 |
2005-11-08 |
Hewlett-Packard Development Company, L.P. |
Method and dosage form for dispensing a bioactive substance
|
JP2004532894A
(ja)
|
2001-06-13 |
2004-10-28 |
イーラン ファーマスーティカルズ、インコーポレイテッド |
アルツハイマー病を治療するためのアミンジオール
|
GB0114532D0
(en)
*
|
2001-06-14 |
2001-08-08 |
Jagotec Ag |
Novel compositions
|
CA2450748A1
(en)
*
|
2001-06-22 |
2003-01-03 |
Pfizer Products Inc. |
Pharmaceutical compositions containing polymer and drug assemblies
|
DE60203506T2
(de)
*
|
2001-06-22 |
2006-02-16 |
Marie Lindner |
Screening-verfahren mit hohem durchsatz (hts) unter verwendung von labormühlen oder microfluidics
|
EP1269994A3
(en)
*
|
2001-06-22 |
2003-02-12 |
Pfizer Products Inc. |
Pharmaceutical compositions comprising drug and concentration-enhancing polymers
|
US7758890B2
(en)
*
|
2001-06-23 |
2010-07-20 |
Lyotropic Therapeutics, Inc. |
Treatment using dantrolene
|
WO2003002122A1
(en)
*
|
2001-06-27 |
2003-01-09 |
Elan Pharmaceuticals, Inc. |
Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease
|
US7067542B2
(en)
*
|
2001-07-10 |
2006-06-27 |
Pharmacia & Upjohn Company |
Diaminediols for the treatment of Alzheimer's disease
|
BR0211121A
(pt)
*
|
2001-07-10 |
2004-10-26 |
Elan Pharm Inc |
Composto, métodos para o tratamento ou prevenção de doenças e para fabricar um composto, intermediário, e, uso de um composto ou sal
|
GB0208742D0
(en)
|
2002-04-17 |
2002-05-29 |
Bradford Particle Design Ltd |
Particulate materials
|
US20030220310A1
(en)
*
|
2001-07-27 |
2003-11-27 |
Schuh Joseph R. |
Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure
|
US20080305173A1
(en)
*
|
2001-07-31 |
2008-12-11 |
Beuford Arlie Bogue |
Amorphous drug beads
|
DE60220923T2
(de)
*
|
2001-08-06 |
2008-03-06 |
Astrazeneca Ab |
Wässrige dispersion stabiler nanopartikel eines wasserunlöslichen wirkstoffs und ein hilfsstoff wie mittelkettige triglyceride (mct)
|
GB0119480D0
(en)
*
|
2001-08-09 |
2001-10-03 |
Jagotec Ag |
Novel compositions
|
MY169670A
(en)
|
2003-09-03 |
2019-05-08 |
Tibotec Pharm Ltd |
Combinations of a pyrimidine containing nnrti with rt inhibitors
|
CA2458889C
(en)
*
|
2001-08-29 |
2011-06-21 |
Dow Global Technologies Inc. |
A process for preparing crystalline drug particles by means of precipitation
|
US20030054042A1
(en)
*
|
2001-09-14 |
2003-03-20 |
Elaine Liversidge |
Stabilization of chemical compounds using nanoparticulate formulations
|
PT2347654T
(pt)
*
|
2001-09-17 |
2019-05-30 |
Elanco Us Inc |
Formulação para o controlo de piolhos ou carrapatos em bovinos
|
WO2003024425A1
(en)
*
|
2001-09-19 |
2003-03-27 |
Elan Pharma International, Ltd. |
Nanoparticulate insulin formulations
|
US7056906B2
(en)
*
|
2001-09-21 |
2006-06-06 |
Schering Corporation |
Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
|
DK1427409T3
(da)
*
|
2001-09-21 |
2009-01-12 |
Schering Corp |
Fremgangsmåde til behandling eller forhindring af vaskulær inflammation under brug af en eller flere sterolabssorptionsinhibitorer
|
US20030119808A1
(en)
*
|
2001-09-21 |
2003-06-26 |
Schering Corporation |
Methods of treating or preventing cardiovascular conditions while preventing or minimizing muscular degeneration side effects
|
ATE345793T1
(de)
*
|
2001-09-21 |
2006-12-15 |
Schering Corp |
Behandlung von xanthom mittels azetidinon- derivate als hemmer der sterol absorption
|
US7053080B2
(en)
*
|
2001-09-21 |
2006-05-30 |
Schering Corporation |
Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
|
US6872725B2
(en)
*
|
2001-09-25 |
2005-03-29 |
Pharmacia Corporation |
Solid-state forms of N-(2-hydroxyacetyl)-5-(4-piperidyl)-4-(4-pyrimidinyl)-3-(4-chlorophenyl) pyrazole
|
US20060003012A9
(en)
*
|
2001-09-26 |
2006-01-05 |
Sean Brynjelsen |
Preparation of submicron solid particle suspensions by sonication of multiphase systems
|
IL160570A0
(en)
|
2001-09-26 |
2004-07-25 |
Baxter Int |
Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal
|
US7544681B2
(en)
*
|
2001-09-27 |
2009-06-09 |
Ramot At Tel Aviv University Ltd. |
Conjugated psychotropic drugs and uses thereof
|
US6878693B2
(en)
*
|
2001-09-28 |
2005-04-12 |
Solubest Ltd. |
Hydrophilic complexes of lipophilic materials and an apparatus and method for their production
|
US20050227911A1
(en)
*
|
2001-09-28 |
2005-10-13 |
Solubest Ltd. |
Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules
|
US20050233003A1
(en)
*
|
2001-09-28 |
2005-10-20 |
Solubest Ltd. |
Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid
|
US20050191359A1
(en)
*
|
2001-09-28 |
2005-09-01 |
Solubest Ltd. |
Water soluble nanoparticles and method for their production
|
CA2462851A1
(en)
|
2001-10-04 |
2003-04-10 |
Elan Pharmaceuticals, Inc. |
Hydroxypropylamines
|
ATE371442T1
(de)
*
|
2001-10-12 |
2007-09-15 |
Elan Pharma Int Ltd |
Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung
|
ES2625340T3
(es)
*
|
2001-10-15 |
2017-07-19 |
Crititech, Inc. |
Composiciones y métodos para la administración de fármacos escasamente solubles en agua y métodos de tratamiento
|
US7112340B2
(en)
*
|
2001-10-19 |
2006-09-26 |
Baxter International Inc. |
Compositions of and method for preparing stable particles in a frozen aqueous matrix
|
TWI330183B
(ja)
*
|
2001-10-22 |
2010-09-11 |
Eisai R&D Man Co Ltd |
|
CA2465793A1
(en)
*
|
2001-11-07 |
2003-05-15 |
Taffy Williams |
Methods for vascular imaging using nanoparticulate contrast agents
|
OA12846A
(en)
*
|
2001-11-08 |
2006-09-15 |
Elan Pharm Inc |
N,N'-substituted-1,3-diamino-2-hydroxypropane derivatives.
|
US7700851B2
(en)
*
|
2001-11-13 |
2010-04-20 |
U.S. Smokeless Tobacco Company |
Tobacco nicotine demethylase genomic clone and uses thereof
|
MXPA04004713A
(es)
*
|
2001-11-19 |
2005-08-16 |
Pharmacia & Up John Company Ll |
Aminoides utiles en el tratamiento de la enfermedad de alzheimer.
|
WO2003043603A1
(en)
*
|
2001-11-20 |
2003-05-30 |
Advanced Inhalation Research, Inc. |
Particulate compositions for improving solubility of poorly soluble agents
|
DK1455755T3
(da)
*
|
2001-11-20 |
2013-07-15 |
Civitas Therapeutics Inc |
Forbedrede partikelsammensætning til levering i lunge
|
GB0127805D0
(en)
*
|
2001-11-20 |
2002-01-09 |
Smithkline Beecham Plc |
Pharmaceutical composition
|
UA76810C2
(uk)
*
|
2001-12-10 |
2006-09-15 |
Мерк Енд Ко., Інк. |
Фармацевтична композиція антагоніста рецептора тахікініну у формі наночастинок
|
DK1581119T3
(da)
|
2001-12-17 |
2013-05-13 |
Corixa Corp |
Sammensætninger og fremgangsmåder til terapi og diagnose af inflammatoriske tarmsygdomme
|
US7368102B2
(en)
|
2001-12-19 |
2008-05-06 |
Nektar Therapeutics |
Pulmonary delivery of aminoglycosides
|
CA2471400A1
(en)
*
|
2001-12-20 |
2003-07-03 |
Femmepharma, Inc. |
Vaginal delivery of drugs
|
US20030235619A1
(en)
*
|
2001-12-21 |
2003-12-25 |
Christine Allen |
Polymer-lipid delivery vehicles
|
PL216539B1
(pl)
|
2001-12-21 |
2014-04-30 |
Tibotec Pharm Ltd |
Związki fenylosulfonylowe i zastosowanie związków fenylosulfonylowych
|
US20060177495A1
(en)
*
|
2001-12-21 |
2006-08-10 |
Christine Allen |
Polymer-lipid delivery vehicles
|
WO2003057212A1
(en)
*
|
2001-12-26 |
2003-07-17 |
Genelabs Technologies, Inc. |
Polyamide derivatives possessing antibacterial, antifungal or antitumor activity
|
US20030129242A1
(en)
*
|
2002-01-04 |
2003-07-10 |
Bosch H. William |
Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer
|
WO2003059319A1
(en)
*
|
2002-01-14 |
2003-07-24 |
Dow Global Technologies Inc. |
Drug nanoparticles from template emulsions
|
WO2003063868A1
(en)
*
|
2002-02-01 |
2003-08-07 |
Pfizer Products Inc. |
Controlled release pharmaceutical dosage forms of a cholesteryl ester transfer protein inhibitor
|
PL216224B1
(pl)
|
2002-02-01 |
2014-03-31 |
Ariad Pharmaceuticals |
Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie
|
DK1471887T3
(da)
*
|
2002-02-04 |
2010-06-07 |
Elan Pharma Int Ltd |
Nanopartikelkompositioner der har lysozym som overfladestabiliseringsmiddel
|
WO2003070187A2
(en)
|
2002-02-15 |
2003-08-28 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
MY142238A
(en)
|
2002-03-12 |
2010-11-15 |
Tibotec Pharm Ltd |
Broadspectrum substituted benzimidazole sulfonamide hiv protease inhibitors
|
GB0206200D0
(en)
*
|
2002-03-15 |
2002-05-01 |
Glaxo Group Ltd |
Pharmaceutical compositions
|
AU2003230692A1
(en)
*
|
2002-03-20 |
2003-10-08 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of map kinase inhibitors
|
US20080220075A1
(en)
*
|
2002-03-20 |
2008-09-11 |
Elan Pharma International Ltd. |
Nanoparticulate compositions of angiogenesis inhibitors
|
DE60318938T2
(de)
|
2002-03-20 |
2009-01-22 |
Mannkind Corp., Valencia |
Inhalationsgerät
|
JP2005526095A
(ja)
*
|
2002-03-20 |
2005-09-02 |
エラン ファーマ インターナショナル,リミティド |
脆砕性の低い急速溶解投与剤型
|
EP1800666A1
(en)
*
|
2002-03-20 |
2007-06-27 |
Elan Pharma International Limited |
Nanoparticulate compositions of angiogenesis inhibitors
|
AU2003224808A1
(en)
*
|
2002-03-28 |
2003-10-13 |
Imcor Pharmaceutical Company |
Compositions and methods for delivering pharmaceutically active agents using nanoparticulates
|
US7799523B2
(en)
|
2002-04-03 |
2010-09-21 |
Celltech R & D, Inc. |
Association of polymorphisms in the SOST gene region with bone mineral density
|
US20040038303A1
(en)
*
|
2002-04-08 |
2004-02-26 |
Unger Gretchen M. |
Biologic modulations with nanoparticles
|
US7101576B2
(en)
*
|
2002-04-12 |
2006-09-05 |
Elan Pharma International Limited |
Nanoparticulate megestrol formulations
|
DK1494649T3
(da)
*
|
2002-04-12 |
2012-04-10 |
Alkermes Pharma Ireland Ltd |
Nanopartikel-megestrolformuleringer
|
US9101540B2
(en)
*
|
2002-04-12 |
2015-08-11 |
Alkermes Pharma Ireland Limited |
Nanoparticulate megestrol formulations
|
US20100226989A1
(en)
*
|
2002-04-12 |
2010-09-09 |
Elan Pharma International, Limited |
Nanoparticulate megestrol formulations
|
US20040105889A1
(en)
*
|
2002-12-03 |
2004-06-03 |
Elan Pharma International Limited |
Low viscosity liquid dosage forms
|
US7582284B2
(en)
|
2002-04-17 |
2009-09-01 |
Nektar Therapeutics |
Particulate materials
|
DE10218109A1
(de)
*
|
2002-04-23 |
2003-11-20 |
Jenapharm Gmbh |
Verfahren zum Herstellen von Kristallen, danach erhältliche Kristalle und deren Verwendung in pharmazeutischen Formulierungen
|
US8501232B2
(en)
*
|
2002-04-23 |
2013-08-06 |
Nanotherapeutics, Inc. |
Process of forming and modifying particles and compositions produced thereby
|
WO2004058686A1
(en)
*
|
2002-04-30 |
2004-07-15 |
Elan Pharmaceuticals, Inc. |
Hydroxypropyl amides for the treatment of alzheimer’s disease
|
JP2005529911A
(ja)
*
|
2002-05-06 |
2005-10-06 |
エラン ファーマ インターナショナル,リミティド |
ナノ粒子ナイスタチン製剤
|
IL165043A0
(en)
|
2002-05-17 |
2005-12-18 |
Tibotec Pharm Ltd |
broadspectrum substituted benzisoxazole sulfonamide hiv protease inhibitors
|
EP1509256B1
(en)
|
2002-05-24 |
2009-07-22 |
Angiotech International Ag |
Compositions and methods for coating medical implants
|
US8313760B2
(en)
|
2002-05-24 |
2012-11-20 |
Angiotech International Ag |
Compositions and methods for coating medical implants
|
US20070264348A1
(en)
*
|
2002-05-24 |
2007-11-15 |
Elan Pharma International, Ltd. |
Nanoparticulate fibrate formulations
|
CA2488499C
(en)
*
|
2002-06-10 |
2013-03-19 |
Elan Pharma International Ltd. |
Nanoparticulate formulations comprising hmg coa reductase inhibitor derivatives ("statins"),combinations thereof as well as manufacturing of these pharmaceutical compositions
|
AU2003241477A1
(en)
*
|
2002-06-10 |
2003-12-22 |
Elan Pharma International, Ltd. |
Nanoparticulate polycosanol formulations and novel polycosanol combinations
|
JP4776229B2
(ja)
|
2002-07-16 |
2011-09-21 |
エラン ファーマ インターナショナル,リミティド |
安定なナノ粒子活性物質の液体投与組成物
|
GB0216700D0
(en)
*
|
2002-07-18 |
2002-08-28 |
Astrazeneca Ab |
Process
|
US20030017208A1
(en)
*
|
2002-07-19 |
2003-01-23 |
Francis Ignatious |
Electrospun pharmaceutical compositions
|
AR040588A1
(es)
*
|
2002-07-26 |
2005-04-13 |
Schering Corp |
Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
|
AU2002950426A0
(en)
*
|
2002-07-29 |
2002-09-12 |
Patrick John Shanahan |
Anti microbial oro-dental system
|
DE10234784A1
(de)
*
|
2002-07-30 |
2004-02-19 |
Günenthal GmbH |
Intravenös applizierbare, pharmazeutische Darreichungsform
|
US7838034B2
(en)
|
2002-07-30 |
2010-11-23 |
Grunenthal Gmbh |
Intravenous pharmaceutical form of administration
|
US20040023935A1
(en)
*
|
2002-08-02 |
2004-02-05 |
Dey, L.P. |
Inhalation compositions, methods of use thereof, and process for preparation of same
|
US20040028747A1
(en)
*
|
2002-08-06 |
2004-02-12 |
Tucker Christopher J. |
Crystalline drug particles prepared using a controlled precipitation process
|
US20040028746A1
(en)
*
|
2002-08-06 |
2004-02-12 |
Sonke Svenson |
Crystalline drug particles prepared using a controlled precipitation (recrystallization) process
|
EP2111856A3
(en)
*
|
2002-08-12 |
2014-09-10 |
Bend Research, Inc. |
Pharmaceutical compositions of semi-ordered drugs and polymers
|
AP2126A
(en)
|
2002-08-14 |
2010-06-03 |
Tibotec Pharm Ltd |
Broadspectrum substituted oxindole sulfonamide HIVprotease inhibitors
|
US7445796B2
(en)
*
|
2002-08-19 |
2008-11-04 |
L. Perrigo Company |
Pharmaceutically active particles of a monomodal particle size distribution and method
|
AU2003296897A1
(en)
*
|
2002-08-20 |
2004-05-04 |
Neopharm, Inc. |
Pharmaceutical formulations of camptothecine derivatives
|
US20060030578A1
(en)
*
|
2002-08-20 |
2006-02-09 |
Neopharm, Inc. |
Pharmaceutically active lipid based formulation of irinotecan
|
UY27939A1
(es)
|
2002-08-21 |
2004-03-31 |
Glaxo Group Ltd |
Compuestos
|
AU2003262911A1
(en)
*
|
2002-08-29 |
2004-03-19 |
Scios Inc. |
Methods of promoting osteogenesis
|
WO2004019937A1
(en)
*
|
2002-09-02 |
2004-03-11 |
Sun Pharmaceutical Industries Limited |
Pharmaceutical composition of metaxalone with enhanced oral bioavailability
|
DE60334924D1
(de)
*
|
2002-09-11 |
2010-12-23 |
Elan Pharma Int Ltd |
Anoteilchengrösse
|
WO2004053056A2
(en)
*
|
2002-09-24 |
2004-06-24 |
University Of Kentucky Research Foundation |
Nanoparticle-based vaccine delivery system containing adjuvant
|
CA2500908A1
(en)
*
|
2002-10-04 |
2004-04-22 |
Elan Pharma International Limited |
Gamma irradiation of solid nanoparticulate active agents
|
US20040105881A1
(en)
*
|
2002-10-11 |
2004-06-03 |
Gregor Cevc |
Aggregates with increased deformability, comprising at least three amphipats, for improved transport through semi-permeable barriers and for the non-invasive drug application in vivo, especially through the skin
|
EP1562555A2
(en)
*
|
2002-10-24 |
2005-08-17 |
Enos Pharmaceuticals, Inc. |
Sustained release l-arginine formulations and methods of manufacture and use
|
US20080145424A1
(en)
*
|
2002-10-24 |
2008-06-19 |
Enos Phramaceuticals, Inc. |
Sustained release L-arginine formulations and methods of manufacture and use
|
JP2006508188A
(ja)
*
|
2002-11-06 |
2006-03-09 |
シェーリング コーポレイション |
脱髄の処置のためのコレステロール吸収インヒビター
|
EP1585502B9
(en)
*
|
2002-11-12 |
2012-05-09 |
Elan Pharma International Limited |
Fast-disintegrating solid dosage forms being not friable and comprising pullulan
|
GB0227443D0
(en)
*
|
2002-11-25 |
2002-12-31 |
Glaxo Group Ltd |
Pyrimidine derivatives
|
EP1565428A1
(en)
|
2002-11-27 |
2005-08-24 |
Elan Pharmaceuticals, Inc. |
Substituted ureas and carbamates
|
CN100513398C
(zh)
|
2002-12-03 |
2009-07-15 |
Axys药物公司 |
作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物
|
US20050095267A1
(en)
*
|
2002-12-04 |
2005-05-05 |
Todd Campbell |
Nanoparticle-based controlled release polymer coatings for medical implants
|
US20040109826A1
(en)
*
|
2002-12-06 |
2004-06-10 |
Dey, L.P. |
Stabilized albuterol compositions and method of preparation thereof
|
WO2004053107A2
(en)
*
|
2002-12-06 |
2004-06-24 |
Scios Inc. |
Methods for treating diabetes
|
AU2002356294A1
(en)
*
|
2002-12-13 |
2004-07-09 |
Jagotec Ag |
A topical nanoparticulate spironolactone formulation
|
US20040173696A1
(en)
*
|
2002-12-17 |
2004-09-09 |
Elan Pharma International Ltd. |
Milling microgram quantities of nanoparticulate candidate compounds
|
EP1583771B1
(en)
|
2002-12-20 |
2013-04-03 |
Celera Corporation |
Genetic polymorphisms associated with myocardial infarction, methods of detection and uses thereof
|
GB0230087D0
(en)
*
|
2002-12-24 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
GB0230088D0
(en)
*
|
2002-12-24 |
2003-01-29 |
Astrazeneca Ab |
Therapeutic agents
|
WO2004060322A2
(en)
*
|
2003-01-02 |
2004-07-22 |
Femmepharma Holding Company, Inc. |
Pharmaceutical preparations for treatments of diseases and disorders of the breast
|
US9173836B2
(en)
|
2003-01-02 |
2015-11-03 |
FemmeParma Holding Company, Inc. |
Pharmaceutical preparations for treatments of diseases and disorders of the breast
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
BRPI0406628A
(pt)
|
2003-01-06 |
2005-12-06 |
Corixa Corp |
Determinados compostos de fosfato de aminoalquil glucosaminida e seu uso
|
CA2513064C
(en)
*
|
2003-01-31 |
2009-11-10 |
Elan Pharma International, Ltd. |
Nanoparticulate topiramate formulations
|
US20040208833A1
(en)
*
|
2003-02-04 |
2004-10-21 |
Elan Pharma International Ltd. |
Novel fluticasone formulations
|
GB0302671D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
GB0302673D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
GB0302672D0
(en)
*
|
2003-02-06 |
2003-03-12 |
Astrazeneca Ab |
Pharmaceutical formulations
|
US20100297252A1
(en)
|
2003-03-03 |
2010-11-25 |
Elan Pharma International Ltd. |
Nanoparticulate meloxicam formulations
|
US8512727B2
(en)
*
|
2003-03-03 |
2013-08-20 |
Alkermes Pharma Ireland Limited |
Nanoparticulate meloxicam formulations
|
US7459442B2
(en)
|
2003-03-07 |
2008-12-02 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
US7235543B2
(en)
|
2003-03-07 |
2007-06-26 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
CA2517573C
(en)
|
2003-03-07 |
2011-12-06 |
Schering Corporation |
Substituted azetidinone compounds, formulations and uses thereof for the treatment of hypercholesterolemia
|
US7208486B2
(en)
|
2003-03-07 |
2007-04-24 |
Schering Corporation |
Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
|
US20040184995A1
(en)
*
|
2003-03-17 |
2004-09-23 |
Yamanouchi Pharmaceutical Co., Ltd. |
Novel dry powder inhalation for lung-delivery and manufacturing method thereof
|
EP2359817B1
(en)
|
2003-03-28 |
2018-01-10 |
Sigmoid Pharma Limited |
Solid oral dosage form containing seamless microcapsules
|
US8747908B2
(en)
|
2003-04-09 |
2014-06-10 |
Osmose, Inc. |
Micronized wood preservative formulations
|
US8637089B2
(en)
|
2003-04-09 |
2014-01-28 |
Osmose, Inc. |
Micronized wood preservative formulations
|
SG163438A1
(en)
*
|
2003-04-09 |
2010-08-30 |
Osmose Inc |
Micronized wood preservative formulations
|
PE20050420A1
(es)
*
|
2003-04-21 |
2005-06-13 |
Elan Pharm Inc |
Fenacilo 2-hidroxi-3-diaminoalcanos
|
PE20050142A1
(es)
*
|
2003-04-21 |
2005-03-21 |
Elan Pharm Inc |
2-hidroxi-3-diaminoalcanos de benzamida
|
US20050244503A1
(en)
*
|
2003-05-19 |
2005-11-03 |
Rabinow Barrett E |
Small-particle pharmaceutical formulations of antiseizure and antidementia agents and immunosuppressive agents
|
WO2004103345A2
(fr)
*
|
2003-05-20 |
2004-12-02 |
L'oreal |
Particules stabilisees en taille par copolymere diacide
|
FR2855051B1
(fr)
*
|
2003-05-20 |
2006-08-25 |
Oreal |
Particules stabilisees en taille par copolymere diacide
|
JP2007501683A
(ja)
*
|
2003-05-22 |
2007-02-01 |
エラン ファーマ インターナショナル リミテッド |
γ線照射によるナノ粒子活性物質分散体の滅菌法
|
DE602004022046D1
(de)
*
|
2003-05-22 |
2009-08-27 |
Applied Nanosystems Bv |
Herstellung von kleinen teilchen
|
US7459146B2
(en)
*
|
2003-05-30 |
2008-12-02 |
3M Innovative Properties Company |
Stabilized aerosol dispersions
|
US7109247B2
(en)
*
|
2003-05-30 |
2006-09-19 |
3M Innovative Properties Company |
Stabilized particle dispersions containing nanoparticles
|
DE10325989A1
(de)
*
|
2003-06-07 |
2005-01-05 |
Glatt Gmbh |
Verfahren zur Herstellung von und daraus resultierende Mikropellets sowie deren Verwendung
|
EP1636270B1
(en)
|
2003-06-16 |
2016-07-20 |
UCB Pharma S.A. |
Antibodies specific for sclerostin and methods for increasing bone mineralization
|
JP4971790B2
(ja)
|
2003-06-17 |
2012-07-11 |
オズモウズ,インコーポレーテッド |
微粒子状木材保存剤及びその製造方法
|
GB0314057D0
(en)
*
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
AU2004247615B2
(en)
*
|
2003-06-18 |
2008-02-21 |
Astrazeneca Ab |
2-substituted 5,6-diaryl-pyrazine derivatives as CB1 modulators
|
GB0314261D0
(en)
*
|
2003-06-19 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
US8986736B2
(en)
*
|
2003-06-24 |
2015-03-24 |
Baxter International Inc. |
Method for delivering particulate drugs to tissues
|
EP1663158A2
(en)
*
|
2003-06-24 |
2006-06-07 |
Baxter International Inc. |
Specific delivery of drugs to the brain
|
TWI359675B
(en)
|
2003-07-10 |
2012-03-11 |
Dey L P |
Bronchodilating β-agonist compositions
|
US8308682B2
(en)
|
2003-07-18 |
2012-11-13 |
Broncus Medical Inc. |
Devices for maintaining patency of surgically created channels in tissue
|
US20050042177A1
(en)
*
|
2003-07-23 |
2005-02-24 |
Elan Pharma International Ltd. |
Novel compositions of sildenafil free base
|
WO2005013938A1
(ja)
*
|
2003-08-06 |
2005-02-17 |
Eisai Co., Ltd. |
薬物超微粒子の製造法及び製造装置
|
JP2007501839A
(ja)
*
|
2003-08-08 |
2007-02-01 |
エラン ファーマ インターナショナル リミテッド |
新規メタキサロン組成物
|
US7419996B2
(en)
*
|
2003-08-13 |
2008-09-02 |
The University Of Houston |
Parenteral and oral formulations of benzimidazoles
|
GB0319797D0
(en)
*
|
2003-08-26 |
2003-09-24 |
Leuven K U Res & Dev |
Particle size reduction of poorly soluble drugs
|
WO2005020933A2
(en)
*
|
2003-09-02 |
2005-03-10 |
University Of South Florida |
Nanoparticles for drug-delivery
|
CA2537413A1
(en)
*
|
2003-09-02 |
2005-03-10 |
Imran Ahmed |
Sustained release dosage forms of ziprasidone
|
WO2005023242A1
(en)
|
2003-09-11 |
2005-03-17 |
Tibotec Pharmaceuticals Ltd. |
Entry inhibitors of the hiv virus
|
GB0327723D0
(en)
*
|
2003-09-15 |
2003-12-31 |
Vectura Ltd |
Pharmaceutical compositions
|
DK1663321T3
(da)
|
2003-09-22 |
2012-11-19 |
Baxter Int |
Højtrykssterilisation til slutsterilisation af farmaceutiske præparater og medicinske produkter
|
EP1675619A4
(en)
*
|
2003-09-29 |
2010-10-06 |
Palmetto Pharmaceuticals Llc |
EXTENDED RELEASE ARGININE FORMULATIONS, METHODS OF MAKING, AND USES
|
WO2005032551A1
(en)
*
|
2003-09-30 |
2005-04-14 |
Scios Inc. |
TREATMENT OF CARDIOVASCULAR DISEASE WITH INHIBITORS OF p38 KINASE
|
PT1685126E
(pt)
*
|
2003-10-16 |
2007-04-30 |
Teva Pharma |
Preparação de candesartan cilexetil
|
US7338171B2
(en)
*
|
2003-10-27 |
2008-03-04 |
Jen-Chuen Hsieh |
Method and apparatus for visual drive control
|
AU2003303744A1
(en)
*
|
2003-10-31 |
2005-06-17 |
Elan Pharma International Ltd. |
Novel nimesulide compositions
|
CA2544627A1
(en)
*
|
2003-11-05 |
2005-05-19 |
Elan Pharma International Ltd. |
Nanoparticulate compositions having a peptide as a surface stabilizer
|
US20050096307A1
(en)
*
|
2003-11-05 |
2005-05-05 |
Schering Corporation |
Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
|
CA2536188A1
(en)
*
|
2003-11-20 |
2005-06-09 |
Angiotech International Ag |
Electrical devices and anti-scarring agents
|
CZ300438B6
(cs)
*
|
2003-11-25 |
2009-05-20 |
Pliva Hrvatska D.O.O. |
Zpusob prípravy orální pevné lékové formy s okamžitým uvolnováním úcinné látky obsahující jako úcinnou látku polymorfní formu finasteridu
|
US20050258288A1
(en)
*
|
2003-11-26 |
2005-11-24 |
E. I. Du Pont De Nemours And Company |
High pressure media milling system and process of forming particles
|
EP1711622A2
(en)
|
2003-11-26 |
2006-10-18 |
Applera Corporation |
Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
|
WO2005051511A1
(ja)
*
|
2003-11-28 |
2005-06-09 |
Mitsubishi Chemical Corporation |
有機化合物微粒子の製造方法
|
US9115090B2
(en)
*
|
2003-12-02 |
2015-08-25 |
The Ohio State University Research Foundation |
Zn2+-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
|
KR100603974B1
(ko)
|
2003-12-05 |
2006-07-25 |
김갑식 |
고체상 지질을 용매로 이용한 나노수준의 또는 비결정질입자의 제조 방법
|
WO2005067964A1
(en)
*
|
2004-01-12 |
2005-07-28 |
Mannkind Corporation |
A method of reducing serum proinsulin levels in type 2 diabetics
|
EP1729755A1
(en)
*
|
2004-01-21 |
2006-12-13 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using aspartyl-protease inihibitors
|
US8957034B2
(en)
*
|
2004-01-28 |
2015-02-17 |
Johns Hopkins University |
Drugs and gene carrier particles that rapidly move through mucous barriers
|
US20050169978A1
(en)
*
|
2004-01-29 |
2005-08-04 |
Shu-Wen Fu |
Wet-micro grinding
|
WO2005072706A2
(en)
*
|
2004-01-29 |
2005-08-11 |
Baxter International Inc. |
Nanosuspensions of anti-retroviral agents for increased central nervous system delivery
|
US7692023B2
(en)
*
|
2004-02-11 |
2010-04-06 |
Teva Pharmaceutical Industries Ltd. |
Candesartan cilexetil polymorphs
|
WO2005087714A2
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Methods of treatment of amyloidosis using bi-cyclic aspartyl protease inhibitors
|
EP1735293A2
(en)
*
|
2004-03-09 |
2006-12-27 |
Elan Pharmaceuticals, Inc. |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
WO2005087215A1
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Substituted urea and carbamate, phenacyl-2-hydroxy-3-diaminoalkane, and benzamide-2-hydroxy-3-diaminoalkane aspartyl-protease inhibitors
|
WO2005087751A2
(en)
*
|
2004-03-09 |
2005-09-22 |
Elan Pharmaceuticals, Inc. |
Substituted hydroxyethylamine aspartyl protease inhibitors
|
US20060014737A1
(en)
*
|
2004-03-09 |
2006-01-19 |
Varghese John |
Methods of treatment of amyloidosis using bi-aryl aspartyl protease inhibitors
|
US20080090753A1
(en)
|
2004-03-12 |
2008-04-17 |
Biodel, Inc. |
Rapid Acting Injectable Insulin Compositions
|
EP1730751B1
(en)
*
|
2004-03-12 |
2009-10-21 |
The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin |
A magnetoresistive medium
|
US20050203482A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Chinea Vanessa I. |
Pharmaceutical dispensing apparatus and method
|
US20050202051A1
(en)
*
|
2004-03-15 |
2005-09-15 |
Chinea Vanessa I. |
Pharmaceutical vehicle
|
AR048193A1
(es)
*
|
2004-03-30 |
2006-04-05 |
Smithkline Beecham Corp |
Procedimiento para la preparacion de una composicion secada por pulverizacion que comprende talnetant, composicion farmaceutica obtenida segun dicho procedimiento y forma de dosificacion que comprende la mencionada composicion
|
DK1731138T3
(en)
*
|
2004-03-31 |
2016-06-06 |
Toyama Chemical Co Ltd |
Fine dispersion of sparingly soluble drug and the process for preparing the
|
AR048650A1
(es)
|
2004-05-04 |
2006-05-10 |
Tibotec Pharm Ltd |
Derivados de (1,10b-dihidro-2-(aminocarbonil-fenil)-5h-pirazolo[1,5 c][1,3]benzoxazin-5-il)fenil metanona como inhibidores de la replicacion viral del vih
|
CN1953973A
(zh)
*
|
2004-05-05 |
2007-04-25 |
特瓦制药工业有限公司 |
高纯度坎地沙坦酯的制备
|
AU2005244121B2
(en)
|
2004-05-07 |
2012-01-19 |
Sequoia Pharmaceuticals, Inc. |
Resistance-repellent retroviral protease inhibitors
|
CA2566256C
(en)
|
2004-05-07 |
2015-07-07 |
Applera Corporation |
Genetic polymorphisms associated with liver fibrosis methods of detection and uses thereof
|
US7316738B2
(en)
*
|
2004-10-08 |
2008-01-08 |
Phibro-Tech, Inc. |
Milled submicron chlorothalonil with narrow particle size distribution, and uses thereof
|
BRPI0511175A
(pt)
|
2004-05-17 |
2007-12-04 |
Tibotec Pharm Ltd |
1-hetero-ciclil-1,5-diidro-pirido[3,2-b]indol-2-onas
|
ATE481403T1
(de)
|
2004-05-17 |
2010-10-15 |
Tibotec Pharm Ltd |
Substituierte 1-phenyl-1,5-dihydro-pyridoä3,2- büindol-2-on-derivate verwendbar als pharmazeutische antiinfektiva
|
CN1953982B
(zh)
|
2004-05-17 |
2011-07-06 |
泰博特克药品有限公司 |
4-取代-1,5-二氢-吡啶并[3,2-b]吲哚-2-酮
|
US20050252408A1
(en)
|
2004-05-17 |
2005-11-17 |
Richardson H W |
Particulate wood preservative and method for producing same
|
US20080199493A1
(en)
|
2004-05-25 |
2008-08-21 |
Picker Louis J |
Siv and Hiv Vaccination Using Rhcmv- and Hcmv-Based Vaccine Vectors
|
US8216610B2
(en)
*
|
2004-05-28 |
2012-07-10 |
Imaginot Pty Ltd. |
Oral paracetamol formulations
|
ES2624585T3
(es)
*
|
2004-05-28 |
2017-07-17 |
Imaginot Pty Ltd. |
Sistema de suministro de compuesto terapéutico oral
|
US8445431B2
(en)
*
|
2004-06-01 |
2013-05-21 |
The Ohio State University |
Ligands having metal binding ability and targeting properties
|
US8012457B2
(en)
|
2004-06-04 |
2011-09-06 |
Acusphere, Inc. |
Ultrasound contrast agent dosage formulation
|
RU2006144851A
(ru)
*
|
2004-06-15 |
2008-06-20 |
Бакстер Интернэшнл Инк. (Us) |
Применение терапевтических средств ex-vivo в виде твердых микрочастиц
|
WO2006002088A2
(en)
*
|
2004-06-21 |
2006-01-05 |
The Ohio State University Research Foundation |
Amino-quinazoline derivatives as antitumor agents
|
AU2005265354A1
(en)
*
|
2004-07-09 |
2006-01-26 |
Elan Pharmaceuticals, Inc. |
Oxime derivative hydroxyethylamine aspartyl-protease inhibitors
|
JP2008505930A
(ja)
*
|
2004-07-09 |
2008-02-28 |
エラン ファーマシューティカルズ,インコーポレイテッド |
オキシム誘導体置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬
|
CA2574767C
(en)
|
2004-07-19 |
2015-02-17 |
Celator Pharmaceuticals, Inc. |
Particulate constructs for release of active agents
|
US8409167B2
(en)
|
2004-07-19 |
2013-04-02 |
Broncus Medical Inc |
Devices for delivering substances through an extra-anatomic opening created in an airway
|
EP1778209B8
(en)
*
|
2004-08-18 |
2010-06-16 |
Concordia Pharmaceuticals, Inc. |
Methods and compositions for oral delivery of fts
|
KR20070043894A
(ko)
*
|
2004-08-19 |
2007-04-25 |
알자 코포레이션 |
제어 방출형 나노입자 활성제 제제 제형 및 방법
|
WO2006023849A2
(en)
|
2004-08-20 |
2006-03-02 |
Mannkind Corporation |
Catalysis of diketopiperazine synthesis
|
GB0418791D0
(en)
*
|
2004-08-23 |
2004-09-22 |
Glaxo Group Ltd |
Novel process
|
JP4990142B2
(ja)
|
2004-08-23 |
2012-08-01 |
マンカインド コーポレイション |
薬物送達のためのジケトピペラジン塩、ジケトモルホリン塩、又はジケトジオキサン塩
|
WO2006026502A1
(en)
|
2004-08-27 |
2006-03-09 |
The Dow Chemical Company |
Enhanced delivery of drug compositions to treat life threatening infections
|
EP1802574A2
(en)
*
|
2004-08-27 |
2007-07-04 |
Elan Pharmaceuticals Inc. |
Methods of treatment of amyloidosis using ethanol cyclicamine derivatives aspartyl protease inhibitors
|
WO2006028074A1
(ja)
*
|
2004-09-07 |
2006-03-16 |
Mitsubishi Chemical Corporation |
微粒子化された物質の製造方法および微粒子化された物質
|
WO2006034147A2
(en)
*
|
2004-09-16 |
2006-03-30 |
Abraxis Bioscience, Inc. |
Compositions and methods for the preparation and administration of poorly water soluble drugs
|
CA2581764A1
(en)
*
|
2004-09-27 |
2006-04-06 |
Sigmoid Biotechnologies Limited |
Minicapsule formulations
|
US7426948B2
(en)
*
|
2004-10-08 |
2008-09-23 |
Phibrowood, Llc |
Milled submicron organic biocides with narrow particle size distribution, and uses thereof
|
CA2584254A1
(en)
*
|
2004-10-14 |
2006-04-27 |
Osmose, Inc. |
Micronized wood preservative formulations in organic carriers
|
KR100651728B1
(ko)
*
|
2004-11-10 |
2006-12-06 |
한국전자통신연구원 |
정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
|
KR20070086045A
(ko)
*
|
2004-11-12 |
2007-08-27 |
이데아 아게 |
피부 상태 치료에서의 확대된 표면 집합체
|
US20090155331A1
(en)
*
|
2005-11-16 |
2009-06-18 |
Elan Pharma International Limited |
Injectable nanoparticulate olanzapine formulations
|
CA2587710C
(en)
*
|
2004-11-16 |
2014-10-21 |
Elan Pharma International Ltd. |
Injectable nanoparticulate olanzapine formulations
|
US7414031B2
(en)
*
|
2004-11-22 |
2008-08-19 |
Genelabs Technologies, Inc. |
5-nitro-nucleoside compounds for treating viral infections
|
UA89513C2
(uk)
*
|
2004-12-03 |
2010-02-10 |
Элан Фарма Интернешнл Лтд. |
Стабільна композиція з наночастинок ралоксифену гідрохлориду
|
EP1839502A4
(en)
*
|
2004-12-07 |
2010-03-24 |
Ajinomoto Kk |
FINE AMINO ACID POWDER AND SUSPENSION THEREOF
|
WO2006062875A1
(en)
*
|
2004-12-08 |
2006-06-15 |
Merck & Co., Inc. |
Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor
|
EP1835889A1
(en)
*
|
2004-12-15 |
2007-09-26 |
Elan Pharma International Limited |
Nanoparticulate tacrolimus formulations
|
WO2006073061A1
(ja)
*
|
2004-12-17 |
2006-07-13 |
Mitsubishi Chemical Corporation |
新規なコアーシェル構造体
|
US20060159767A1
(en)
*
|
2004-12-22 |
2006-07-20 |
Elan Pharma International Limited |
Nanoparticulate bicalutamide formulations
|
AU2005321751B2
(en)
*
|
2004-12-31 |
2012-04-05 |
Iceutica Pty Ltd |
Nanoparticle composition and methods for synthesis thereof
|
CA2858733C
(en)
*
|
2004-12-31 |
2017-12-19 |
Iceutica Pty Ltd |
Nanoparticle compositions and methods for synthesis thereof
|
AU2012201630B8
(en)
*
|
2004-12-31 |
2014-03-06 |
Iceutica Pty Ltd |
NanoParticle Composition(s) and Method for Synthesis Thereof
|
JP2008526855A
(ja)
*
|
2005-01-06 |
2008-07-24 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子のカンデサルタン製剤
|
EP1834624A4
(en)
*
|
2005-01-07 |
2011-05-04 |
Eisai R&D Man Co Ltd |
MEDICAL COMPOSITION AND MANUFACTURING METHOD THEREFOR
|
US8623405B2
(en)
*
|
2005-01-28 |
2014-01-07 |
Takeda Pharmaceutical Company Limited |
Finely divided composition containing poorly water soluble substance
|
ES2265262B1
(es)
*
|
2005-01-31 |
2008-03-01 |
Activery Biotech, S.L.(Titular Al 50%) |
Procedimiento para la obtencion de sistemas micro- y nanodispersos.
|
ATE540970T1
(de)
|
2005-02-08 |
2012-01-15 |
Res Dev Foundation |
Zusammensetzungen in zusammenhang mit löslichen, g-proteingekoppelten rezeptoren (sgpcrs)
|
MX2007009915A
(es)
*
|
2005-02-15 |
2007-11-06 |
Elan Pharma Int Ltd |
Formulaciones en aerosol e inyectables de benzodiazepina nanoparticulada.
|
MX2007010460A
(es)
*
|
2005-02-28 |
2007-11-08 |
Genelabs Tech Inc |
Compuestos de nucleosido triciclico para tratar infecciones virales.
|
AU2005100176A4
(en)
*
|
2005-03-01 |
2005-04-07 |
Gym Tv Pty Ltd |
Garbage bin clip
|
CA2598288A1
(en)
*
|
2005-03-03 |
2006-09-14 |
Elan Pharma International Limited |
Nanoparticulate compositions of heterocyclic amide derivatives
|
US20060204588A1
(en)
*
|
2005-03-10 |
2006-09-14 |
Elan Pharma International Limited |
Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof
|
EP1856296A2
(en)
|
2005-03-11 |
2007-11-21 |
Applera Corporation |
Genetic polymorphisms associated with coronary heart disease, methods of detection and uses thereof
|
EA200701987A1
(ru)
*
|
2005-03-16 |
2008-02-28 |
Элан Фарма Интернэшнл Лтд. |
Составы из нанодисперсного антагониста лейкотриеновых рецепторов/кортикостероида
|
WO2006102117A1
(en)
*
|
2005-03-17 |
2006-09-28 |
Elan Pharma International Limited |
Nanoparticulate biphosphonate compositions
|
WO2006102494A2
(en)
*
|
2005-03-23 |
2006-09-28 |
Elan Pharma International Limited |
Nanoparticulate corticosteroid and antihistamine formulations
|
US20070224282A1
(en)
*
|
2005-03-28 |
2007-09-27 |
Toyama Chemical Co., Ltd. |
Fine Dispersion of Sparingly Soluble Drug and Process for Producing the Same
|
CN101184504A
(zh)
|
2005-03-31 |
2008-05-21 |
葛兰素史密丝克莱恩生物有限公司 |
针对衣原体感染的疫苗
|
TW200710091A
(en)
|
2005-04-11 |
2007-03-16 |
Tibotec Pharm Ltd |
(1,10B-dihydro-2-(aminoalkyl-phenyl)-5H-pyrazolo [1,5-c][1,3]benzoxazin-5-yl)phenyl methanone derivatives as HIV viral replication inhibitors
|
WO2006110809A2
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International, Limited |
Nanoparticulate lipase inhibitor formulations
|
CA2604735A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Elan Pharma International Limited |
Nanoparticulate quinazoline derivative formulations
|
MX2007012762A
(es)
*
|
2005-04-12 |
2008-01-14 |
Elan Pharma Int Ltd |
Composiciones de material nanoparticulado y de liberacion controlada que comprende ciclosporina.
|
ATE454134T1
(de)
*
|
2005-04-13 |
2010-01-15 |
Abbott Gmbh & Co Kg |
Verfahren zur schonenden herstellung hochfeiner partikelsuspensionen und hochfeiner partikel sowie deren verwendung
|
US20080305161A1
(en)
*
|
2005-04-13 |
2008-12-11 |
Pfizer Inc |
Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
|
GB2442366A
(en)
*
|
2005-04-13 |
2008-04-02 |
Elan Pharma Int Ltd |
Nanoparticulate and controlled release compositions comprising prostaglandin derivatives
|
MX2007012103A
(es)
*
|
2005-04-13 |
2007-11-20 |
Pfizer Prod Inc |
Formulaciones deposito inyectables y metodos para proporcionar una liberacion sostenida de composiciones de nanoparticulas.
|
ITMI20050739A1
(it)
*
|
2005-04-22 |
2006-10-23 |
Effebi Spa |
Piastrina di connsessione valvola-attuatore
|
TW200720285A
(en)
*
|
2005-04-25 |
2007-06-01 |
Genelabs Tech Inc |
Nucleoside compounds for treating viral infections
|
CA2821389C
(en)
|
2005-04-29 |
2015-11-17 |
Glaxosmithkline Biologicals S.A. |
Novel method for preventing or treating m tuberculosis infection
|
US7592429B2
(en)
|
2005-05-03 |
2009-09-22 |
Ucb Sa |
Sclerostin-binding antibody
|
US8003108B2
(en)
|
2005-05-03 |
2011-08-23 |
Amgen Inc. |
Sclerostin epitopes
|
JP2008540546A
(ja)
*
|
2005-05-10 |
2008-11-20 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子クロピドグレル製剤
|
ES2429941T3
(es)
*
|
2005-05-10 |
2013-11-18 |
Teva Pharmaceutical Industries, Ltd. |
Candesartán cilexetilo micronizado estable y métodos para preparar el mismo
|
JP2008540550A
(ja)
*
|
2005-05-10 |
2008-11-20 |
エラン・ファルマ・インターナショナル・リミテッド |
ビタミンk2を含むナノ粒子および制御放出組成物
|
US20110064803A1
(en)
*
|
2005-05-10 |
2011-03-17 |
Elan Pharma International Limited. |
Nanoparticulate and controlled release compositions comprising vitamin k2
|
WO2008010784A1
(en)
*
|
2005-05-16 |
2008-01-24 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising a cephalosporin
|
BRPI0609982A2
(pt)
*
|
2005-05-23 |
2010-05-18 |
Elan Pharma Int Ltd |
composição nanoparticulada estável, método para preparar uma composição nanoparticulada, uso de uma composição, e, composição de liberação controlada
|
EA015102B1
(ru)
*
|
2005-06-03 |
2011-06-30 |
Элан Фарма Интернэшнл Лтд. |
Препараты наночастиц мезилата иматиниба
|
US20060292214A1
(en)
*
|
2005-06-03 |
2006-12-28 |
Elan Pharma International Limited |
Nanoparticulate acetaminophen formulations
|
US20070042049A1
(en)
*
|
2005-06-03 |
2007-02-22 |
Elan Pharma International, Limited |
Nanoparticulate benidipine compositions
|
MX2007015511A
(es)
*
|
2005-06-07 |
2008-03-06 |
Univ Ramot |
Sales novedosas de farmacos sicotropicos conjugados y procesos para prepararlas.
|
CA2612994A1
(en)
|
2005-06-08 |
2006-12-08 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising cefditoren
|
WO2006135689A2
(en)
*
|
2005-06-09 |
2006-12-21 |
Elan Pharma International, Limited |
Nanoparticulate ebastine formulations
|
EA200800041A1
(ru)
*
|
2005-06-13 |
2008-04-28 |
Элан Фарма Интернэшнл Лтд. |
Составы с наночастицами клопидогреля, содержащие комбинацию клопидогреля и аспирина
|
US20100221327A1
(en)
*
|
2005-06-15 |
2010-09-02 |
Elan Pharma International Limited |
Nanoparticulate azelnidipine formulations
|
CA2613474A1
(en)
*
|
2005-06-20 |
2007-03-08 |
Elan Pharma International Limited |
Nanoparticulate and controlled release compositions comprising aryl-heterocyclic compounds
|
BRPI0612665A2
(pt)
*
|
2005-06-22 |
2010-11-30 |
Elan Pharma Int Ltd |
formulações nanoparticuladas de megestrol
|
KR20080040677A
(ko)
*
|
2005-06-24 |
2008-05-08 |
제네랩스 테크놀로지스, 인코포레이티드 |
바이러스를 치료하기 위한 헤테로아릴 유도체
|
US8951560B2
(en)
*
|
2005-06-29 |
2015-02-10 |
Dsm Ip Assets B.V. |
Isoflavone nanoparticles and use thereof
|
US20090028950A1
(en)
*
|
2005-06-29 |
2009-01-29 |
Mitsubishi Chemical Corporation |
Granule dispersion composition, process for producing the same, and granular material and medicine
|
US8074906B2
(en)
*
|
2005-07-07 |
2011-12-13 |
Nanotherapeutics, Inc. |
Process for milling and preparing powders and compositions produced thereby
|
US20070298109A1
(en)
*
|
2005-07-07 |
2007-12-27 |
The Trustees Of The University Of Pennsylvania |
Nano-scale devices
|
EP1904041A2
(en)
*
|
2005-07-07 |
2008-04-02 |
Elan Pharma International Limited |
Nanoparticulate clarithromycin formulations
|
WO2007011989A2
(en)
*
|
2005-07-15 |
2007-01-25 |
Map Pharmaceuticals, Inc. |
Multiple active pharmaceutical ingredients combined in discrete inhalation particles and formulations thereof
|
WO2007016597A2
(en)
*
|
2005-07-29 |
2007-02-08 |
The Regents Of The University Of California |
Targeting tnf-alpha converting enzyme (tace)-dependent growth factor shedding in cancer therapy
|
BRPI0614757A2
(pt)
*
|
2005-08-10 |
2011-04-12 |
Novartis Ag |
composição farmacêutica, micropartìcula e seu uso
|
US20080213385A1
(en)
*
|
2005-08-10 |
2008-09-04 |
Oskar Kalb |
Formulations for 7- (T-Butoxy) Iminomethyl Camptothecin
|
GB0516549D0
(en)
*
|
2005-08-12 |
2005-09-21 |
Sulaiman Brian |
Milling system
|
US20080193534A1
(en)
*
|
2005-08-12 |
2008-08-14 |
Astrazeneca Ab |
Process
|
CN101291658B
(zh)
|
2005-08-31 |
2014-04-16 |
阿布拉科斯生物科学有限公司 |
用于制备稳定性增加的水难溶性药物的组合物和方法
|
RU2433818C2
(ru)
*
|
2005-08-31 |
2011-11-20 |
АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи |
Композиции, включающие слаборастворимые в воде фармацевтические вещества и противомикробные вещества
|
JPWO2007029660A1
(ja)
*
|
2005-09-06 |
2009-03-19 |
アステラス製薬株式会社 |
腸溶性基剤が表面に吸着した難溶性薬物の微小粒子
|
JP2009507925A
(ja)
*
|
2005-09-13 |
2009-02-26 |
エラン ファーマ インターナショナル リミテッド |
ナノ粒子タダラフィル製剤
|
IN2014DN09128A
(ja)
|
2005-09-14 |
2015-07-10 |
Mannkind Corp |
|
US20070148100A1
(en)
*
|
2005-09-15 |
2007-06-28 |
Elan Pharma International, Limited |
Nanoparticulate aripiprazole formulations
|
US7799530B2
(en)
|
2005-09-23 |
2010-09-21 |
Celera Corporation |
Genetic polymorphisms associated with cardiovascular disorders and drug response, methods of detection and uses thereof
|
US20070086952A1
(en)
*
|
2005-09-29 |
2007-04-19 |
Biodel, Inc. |
Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
|
US7713929B2
(en)
|
2006-04-12 |
2010-05-11 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
US8084420B2
(en)
*
|
2005-09-29 |
2011-12-27 |
Biodel Inc. |
Rapid acting and long acting insulin combination formulations
|
WO2007041079A2
(en)
*
|
2005-09-30 |
2007-04-12 |
Alza Corporation |
Banded controlled release nanoparticle active agent formulation dosage forms and methods
|
EA019255B1
(ru)
|
2005-10-07 |
2014-02-28 |
Экселиксис, Инк. |
Ингибиторы фосфатидилинозит-3-киназы и содержащие их фармацевтические композиции
|
DK1940839T3
(da)
|
2005-10-07 |
2013-10-14 |
Exelixis Inc |
Pyridopyrimidione Inhibitors of P13Ka
|
WO2007047305A1
(en)
*
|
2005-10-12 |
2007-04-26 |
Elan Pharmaceuticals, Inc. |
Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors
|
JP2009511589A
(ja)
*
|
2005-10-12 |
2009-03-19 |
エラン ファーマシューティカルズ,インコーポレイテッド |
アリール−シクロプロピル誘導体のアスパルチルプロテアーゼ阻害剤を使用してアミロイドーシスを治療する方法
|
US7695911B2
(en)
|
2005-10-26 |
2010-04-13 |
Celera Corporation |
Genetic polymorphisms associated with Alzheimer's Disease, methods of detection and uses thereof
|
DE102005053862A1
(de)
*
|
2005-11-04 |
2007-05-10 |
Pharmasol Gmbh |
Verfahren und Vorrichtung zur Herstellung hochfeiner Partikel sowie zur Beschichtung solcher Partikel
|
AU2006318212C1
(en)
|
2005-11-23 |
2012-08-30 |
The Board Of Regents Of The University Of Texas System |
Oncogenic ras-specific cytotoxic compound and methods of use thereof
|
JP2009517346A
(ja)
*
|
2005-11-28 |
2009-04-30 |
イメイジノット ピーティーワイ エルティーディー |
治療用化合物の経口送達系
|
MX2008006888A
(es)
*
|
2005-11-28 |
2008-09-30 |
Marinus Pharmaceuticals |
Formulas y metodos para la manufactura y uso de la ganaxolona.
|
US20120121653A1
(en)
*
|
2005-12-02 |
2012-05-17 |
Elan Pharma International Limited |
Novel mometasone compositions and methods of making and using the same
|
TW200730478A
(en)
*
|
2005-12-12 |
2007-08-16 |
Genelabs Tech Inc |
N-(6-membered aromatic ring)-amido anti-viral compounds
|
US20070249572A1
(en)
*
|
2005-12-20 |
2007-10-25 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
US20070197486A1
(en)
*
|
2005-12-20 |
2007-08-23 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids
|
US20070160542A1
(en)
*
|
2005-12-20 |
2007-07-12 |
Verus Pharmaceuticals, Inc. |
Methods and systems for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070178049A1
(en)
*
|
2005-12-20 |
2007-08-02 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids having an enhanced pharmacokinetic profile
|
US20070185066A1
(en)
*
|
2005-12-20 |
2007-08-09 |
Verus Pharmaceuticals, Inc. |
Systems and methods for the delivery of corticosteroids
|
CN103265495B
(zh)
|
2005-12-29 |
2016-11-16 |
莱西肯医药有限公司 |
多环氨基酸衍生物及其使用方法
|
EP1979488A4
(en)
|
2006-01-09 |
2009-05-27 |
Univ California |
IMMUNOSTIMULATORY COMBINATIONS OF TNFRSF, TLR, NLR, RHR, PURINERGIC RECEPTOR AND CYTOKINE RECEPTOR AGONISTS USED FOR VACCINES AND ANTI-TUMOR IMMUNOTHERAPY
|
CA2642577A1
(en)
*
|
2006-02-15 |
2007-08-23 |
Tika Lakemedel Ab |
Methods of manufacturing corticosteroid solutions
|
BRPI0707991B8
(pt)
|
2006-02-22 |
2021-05-25 |
Mannkind Corp |
métodos de preparação de um medicamento em pó seco com uma propriedade farmacêutica melhorada, dito pó seco e uso de uma quantidade efetiva do pó seco
|
AU2006338839A1
(en)
*
|
2006-02-23 |
2007-08-30 |
Iomedix Sleep International Srl |
Compositions and methods for the induction and maintenance of quality sleep
|
US7649098B2
(en)
|
2006-02-24 |
2010-01-19 |
Lexicon Pharmaceuticals, Inc. |
Imidazole-based compounds, compositions comprising them and methods of their use
|
US8367112B2
(en)
*
|
2006-02-28 |
2013-02-05 |
Alkermes Pharma Ireland Limited |
Nanoparticulate carverdilol formulations
|
US20090099175A1
(en)
*
|
2006-03-01 |
2009-04-16 |
Arrington Mark P |
Phosphodiesterase 10 inhibitors
|
US10137083B2
(en)
|
2006-03-07 |
2018-11-27 |
SGN Nanopharma Inc |
Ophthalmic preparations
|
WO2007103294A2
(en)
*
|
2006-03-07 |
2007-09-13 |
Novavax, Inc. |
Nanoemulsions of poorly soluble pharmaceutical active ingredients and methods of making the same
|
US11311477B2
(en)
|
2006-03-07 |
2022-04-26 |
Sgn Nanopharma Inc. |
Ophthalmic preparations
|
US20090087492A1
(en)
*
|
2006-03-14 |
2009-04-02 |
Merck & Co., Inc. |
Processes and Apparatuses for the Production of Crystalline Organic Microparticle Compositions by Micro-Milling and Crystallization on Micro-Seed and Their Use
|
BRPI0709940A2
(pt)
|
2006-04-03 |
2011-08-02 |
Tibotec Pharm Ltd |
3,4-diidro-imidazo[4,5-b]piridin-5-onas para inibição do hiv
|
CA2649109A1
(en)
*
|
2006-04-12 |
2007-10-25 |
Biodel, Inc. |
Rapid acting and long acting insulin combination formulations
|
US20080299210A1
(en)
*
|
2006-04-13 |
2008-12-04 |
Min Wei |
Stable nanosized amorphous drug
|
EP2010528B1
(en)
|
2006-04-19 |
2017-10-04 |
Novartis AG |
6-o-substituted benzoxazole and benzothiazole compounds and methods of inhibiting csf-1r signaling
|
JP2007306950A
(ja)
|
2006-05-15 |
2007-11-29 |
Osaka Univ |
薬効成分ナノ粒子分散液の製造方法
|
US20070275052A1
(en)
*
|
2006-05-24 |
2007-11-29 |
Glenmark Pharmaceuticals Limited |
Pharmaceutical compositions containing sterol inhibitors
|
SG170047A1
(en)
*
|
2006-05-30 |
2011-04-29 |
Elan Pharma Int Ltd |
Nanoparticulate posaconazole formulations
|
WO2007144362A1
(en)
|
2006-06-14 |
2007-12-21 |
Intervet International B.V. |
A suspension comprising benzimidazole carbamate and a polysorbate
|
US20130197527A1
(en)
*
|
2006-06-12 |
2013-08-01 |
Smith & Nephew, Inc. |
Systems, methods and devices for tibial resection
|
US20080181957A1
(en)
*
|
2006-06-23 |
2008-07-31 |
Min Wei |
Increased amorphous stability of poorly water soluble drugs by nanosizing
|
AU2007262941B2
(en)
|
2006-06-23 |
2013-11-21 |
Janssen Sciences Ireland Uc |
Aqueous suspensions of TMC278
|
WO2008002568A2
(en)
*
|
2006-06-26 |
2008-01-03 |
Mutual Pharmaceutical Company, Inc. |
Active agent formulations, methods of making, and methods of use
|
EA014959B3
(ru)
|
2006-06-28 |
2014-10-30 |
Амген Инк. |
Ингибиторы глицинового переносчика-1
|
IN2014MN00380A
(ja)
*
|
2006-06-30 |
2015-06-19 |
Iceutica Pty Ltd |
|
ZA200810741B
(en)
*
|
2006-06-30 |
2010-05-26 |
Iceutica Ltd |
Methodes for the preparation of biologically active compounds in nanoparticulate form
|
TW200820991A
(en)
*
|
2006-07-10 |
2008-05-16 |
Elan Pharma Int Ltd |
Nanoparticulate sorafenib formulations
|
US8377990B2
(en)
*
|
2006-07-17 |
2013-02-19 |
Ramot At Tel-Aviv University Ltd. |
Conjugates comprising a psychotropic drug or a GABA agonist and an organic acid and their use in treating pain and other CNS disorders
|
RU2009105837A
(ru)
*
|
2006-07-20 |
2010-08-27 |
СмитКлайн Бичем Копэрейшн (US) |
Полициклические противовирусные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусной инфекции с ее помощью и названные соединения для изготовления лекарственных средств
|
KR20090027734A
(ko)
*
|
2006-07-27 |
2009-03-17 |
(주)아모레퍼시픽 |
난용성 약물의 나노입자를 포함하는 분말의 제조방법
|
EP2054056A4
(en)
|
2006-08-16 |
2010-08-25 |
J David Gladstone Inst A Testa |
SMALL MOLECULAR INHIBITORS OF KYNURENINE-3-MONOOXYGENASE
|
DK2054397T3
(en)
*
|
2006-08-16 |
2016-01-18 |
J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone |
SMALL MOLECULAR INHIBITORS OF KYNURENIN-3-MONOOXYGENASE
|
US20090149462A1
(en)
*
|
2006-08-28 |
2009-06-11 |
Hetero Drugs Limited |
Process for purification of aprepitant
|
WO2008030557A2
(en)
*
|
2006-09-08 |
2008-03-13 |
Johns Hopkins University |
Compositions and methods for enhancing transport through mucus
|
CL2007002567A1
(es)
|
2006-09-08 |
2008-02-01 |
Amgen Inc |
Proteinas aisladas de enlace a activina a humana.
|
WO2008085556A2
(en)
|
2006-09-12 |
2008-07-17 |
University Of South Florida |
Surfactant-free nanoparticles for drug delivery
|
US9598462B2
(en)
|
2012-01-26 |
2017-03-21 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
US9481912B2
(en)
|
2006-09-12 |
2016-11-01 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
|
US8097419B2
(en)
|
2006-09-12 |
2012-01-17 |
Longhorn Vaccines & Diagnostics Llc |
Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
|
US8080645B2
(en)
|
2007-10-01 |
2011-12-20 |
Longhorn Vaccines & Diagnostics Llc |
Biological specimen collection/transport compositions and methods
|
WO2008032327A2
(en)
*
|
2006-09-14 |
2008-03-20 |
Yissum Research Development Company Of The Hebrew University Of Jerusalem |
Organic nanoparticles obtained from microemulsions by solvent evaporation
|
AR063704A1
(es)
*
|
2006-09-14 |
2009-02-11 |
Makhteshim Chem Works Ltd |
Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
|
CL2007002689A1
(es)
|
2006-09-18 |
2008-04-18 |
Vitae Pharmaceuticals Inc |
Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
|
BRPI0716890A2
(pt)
*
|
2006-09-22 |
2013-10-22 |
Labopharm Inc |
Composição, e, método de produção de uma composição, de administração de um agente farmaceuticamente ativo insolúvel em água a um mamífero, e de tratamento de câncer em um mamífero
|
CN1946120B
(zh)
*
|
2006-10-20 |
2010-05-12 |
华为技术有限公司 |
实现话单关联的方法及系统
|
CA2915679C
(en)
|
2006-10-20 |
2017-12-12 |
Celera Corporation |
Genetic polymorphisms associated with venous thrombosis, methods of detection and uses thereof
|
US8946200B2
(en)
*
|
2006-11-02 |
2015-02-03 |
Southwest Research Institute |
Pharmaceutically active nanosuspensions
|
US20100036091A1
(en)
*
|
2006-11-10 |
2010-02-11 |
Amgen Inc. |
Antibody-based diagnostics and therapeutics
|
EP2460828A3
(en)
*
|
2006-11-10 |
2012-08-08 |
UCB Pharma, S.A. |
Antibodies and diagnostics
|
US9114077B2
(en)
*
|
2006-11-17 |
2015-08-25 |
Abbvie Deutschland Gmbh & Co Kg |
Nanocrystals for use in topical cosmetic formulations and method of production thereof
|
KR20080047957A
(ko)
*
|
2006-11-27 |
2008-05-30 |
주식회사 엠디바이오알파 |
고혈압의 치료 및 예방을 위한 약제 조성물
|
EP2101735A2
(en)
*
|
2006-11-28 |
2009-09-23 |
Marinus Pharmaceuticals, Inc. |
Nanoparticulate formulations and methods for the making and use thereof
|
WO2008070072A2
(en)
*
|
2006-12-01 |
2008-06-12 |
Mutual Pharmaceutical Company, Inc. |
Carvedilol forms, compositions, and methods of preparation thereof
|
US20090028935A1
(en)
*
|
2006-12-01 |
2009-01-29 |
Kristin Arnold |
Carvedilol forms, compositions, and methods of preparation thereof
|
US20080138405A1
(en)
*
|
2006-12-06 |
2008-06-12 |
Raheja Praveen |
Sirolimus nanodispersion
|
UA99270C2
(en)
|
2006-12-12 |
2012-08-10 |
Лексикон Фармасьютикалз, Инк. |
4-phenyl-6-(2,2,2-trifluoro-1-phenylethoxy)pyrimidine-based compounds and methods of their use
|
US20080153789A1
(en)
*
|
2006-12-26 |
2008-06-26 |
Femmepharma Holding Company, Inc. |
Topical administration of danazol
|
DE102007001473A1
(de)
|
2007-01-08 |
2008-07-10 |
Andreas Lemke |
Verfahren zur Herstellung und Anwendung von Mikro- und/oder Nanosuspensionen durch aufbauende Mikronisierung in Gegenwart von Trockeneis und hohem Druck
|
JP2010517759A
(ja)
*
|
2007-02-09 |
2010-05-27 |
アストラゼネカ・アクチエボラーグ |
水性媒体中における固体非晶質サブミクロン粒子の安定な分散体を製造する方法
|
TW200848039A
(en)
*
|
2007-02-09 |
2008-12-16 |
Astrazeneca Ab |
Pharmaceutical compositions
|
DK2425820T3
(en)
|
2007-02-11 |
2015-07-13 |
Map Pharmaceuticals Inc |
A method for the therapeutic administration of DHE in order to enable quick relief of migraine, while minimizing the adverse event profile
|
WO2008110534A1
(en)
*
|
2007-03-13 |
2008-09-18 |
Sandoz Ag |
Pharmaceutical compositions of poorly soluble drugs
|
AU2008224941C1
(en)
|
2007-03-14 |
2013-06-27 |
Exelixis Patent Company Llc |
Inhibitors of the hedgehog pathway
|
AR065720A1
(es)
|
2007-03-14 |
2009-06-24 |
Tibotec Pharm Ltd |
Polvos para reconstitucion que comprenden rilpivirina dispersos en ciertos polimeros. uso. proceso.
|
US9114071B2
(en)
|
2007-04-04 |
2015-08-25 |
Sigmoid Pharma Limited |
Oral pharmaceutical composition
|
WO2008124522A2
(en)
*
|
2007-04-04 |
2008-10-16 |
Biodel, Inc. |
Amylin formulations
|
TWI405590B
(zh)
*
|
2007-04-06 |
2013-08-21 |
Activus Pharma Co Ltd |
微粉碎化有機化合物粒子之製法
|
DK2191001T3
(en)
|
2007-04-09 |
2016-09-19 |
Univ Florida |
RAAV VECTOR COMPOSITIONS WITH TYROSIN MODIFIED CAPSIDE PROTEINS AND PROCEDURES FOR USE THEREOF
|
JP2010527285A
(ja)
|
2007-04-26 |
2010-08-12 |
シグモイド・ファーマ・リミテッド |
複数のミニカプセルの製造
|
EP2073798A2
(en)
*
|
2007-05-01 |
2009-07-01 |
Sigmoid Pharma Limited |
Pharmaceutical nimodipine compositions
|
WO2008135828A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a drug, ethylcellulose, and a bile salt
|
WO2008135855A2
(en)
|
2007-05-03 |
2008-11-13 |
Pfizer Products Inc. |
Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and a nonionizable polymer
|
EP2152274A4
(en)
*
|
2007-05-07 |
2010-07-21 |
Questor Pharmaceuticals Inc |
NASAL ADMINISTRATION OF BENZODIAZEPINES
|
US8530463B2
(en)
*
|
2007-05-07 |
2013-09-10 |
Hale Biopharma Ventures Llc |
Multimodal particulate formulations
|
EP2152700B1
(en)
|
2007-05-21 |
2013-12-11 |
Novartis AG |
Csf-1r inhibitors, compositions, and methods of use
|
US8722736B2
(en)
|
2007-05-22 |
2014-05-13 |
Baxter International Inc. |
Multi-dose concentrate esmolol with benzyl alcohol
|
US8426467B2
(en)
|
2007-05-22 |
2013-04-23 |
Baxter International Inc. |
Colored esmolol concentrate
|
EP2162386B1
(en)
*
|
2007-05-31 |
2020-03-18 |
The Administrators of the Tulane Educational Fund |
Method of forming stable functionalized nanoparticles
|
WO2008149230A2
(en)
|
2007-06-04 |
2008-12-11 |
Pfizer Products Inc. |
Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate
|
WO2008149192A2
(en)
|
2007-06-04 |
2008-12-11 |
Pfizer Products Inc. |
Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer
|
EP3061462B1
(en)
|
2007-07-02 |
2019-02-27 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
CN101784258B
(zh)
|
2007-07-06 |
2013-07-17 |
M技术株式会社 |
生物摄取物微粒子及其制造方法、分散体、医药组成物
|
EP2175857B1
(en)
|
2007-07-12 |
2013-09-11 |
Janssen R&D Ireland |
Crystalline form of (e) 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
|
US20100266692A1
(en)
|
2007-07-13 |
2010-10-21 |
Corey Jay Bloom |
Nanoparticles comprising a non-ionizable polymer and an anionic cellulosic polymer
|
BRPI0814939A2
(pt)
*
|
2007-08-10 |
2015-01-27 |
Glaxosmithkline Llc |
Entidade química, composição farmacêutica, e, método para tratar uma infecção viral em um mamífero.
|
US11041215B2
(en)
|
2007-08-24 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
PCR ready compositions and methods for detecting and identifying nucleic acid sequences
|
US9683256B2
(en)
|
2007-10-01 |
2017-06-20 |
Longhorn Vaccines And Diagnostics, Llc |
Biological specimen collection and transport system
|
US10004799B2
(en)
|
2007-08-27 |
2018-06-26 |
Longhorn Vaccines And Diagnostics, Llc |
Composite antigenic sequences and vaccines
|
EP2772267B1
(en)
|
2007-08-27 |
2016-04-27 |
Longhorn Vaccines and Diagnostics, LLC |
Immunogenic compositions and methods
|
WO2009029729A1
(en)
*
|
2007-08-31 |
2009-03-05 |
Genelabs Technologies, Inc. |
Amino tricyclic-nucleoside compounds, compositions, and methods of use
|
JP2010537989A
(ja)
|
2007-09-03 |
2010-12-09 |
ナノセラピューティクス・インコーポレイテッド |
難溶性薬物の組成物及び送達方法
|
US20090130210A1
(en)
*
|
2007-09-11 |
2009-05-21 |
Raheja Praveen |
Pharmaceutical compositions of sirolimus
|
US20090068266A1
(en)
*
|
2007-09-11 |
2009-03-12 |
Raheja Praveen |
Sirolimus having specific particle size and pharmaceutical compositions thereof
|
US8232413B2
(en)
*
|
2007-09-12 |
2012-07-31 |
Merck Sharp & Dohme Corp. |
Process for the production of a crystalline glucagon receptor antagonist compound
|
CL2008002775A1
(es)
|
2007-09-17 |
2008-11-07 |
Amgen Inc |
Uso de un agente de unión a esclerostina para inhibir la resorción ósea.
|
HUE043897T2
(hu)
|
2007-09-25 |
2019-09-30 |
Solubest Ltd |
Lipofil hatóanyagot tartalmazó készítmények és eljárás elõállításukra
|
US11041216B2
(en)
|
2007-10-01 |
2021-06-22 |
Longhorn Vaccines And Diagnostics, Llc |
Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
|
DK2195466T3
(da)
|
2007-10-01 |
2013-01-14 |
Longhorn Vaccines & Diagnostics Llc |
Fremgangsmåde til opbevaring af biologiske prøver
|
JP2011500557A
(ja)
*
|
2007-10-11 |
2011-01-06 |
マゼンス インコーポレイテッド |
ナフトキノン系化合物の微粒化粒子を含有する医薬組成物
|
WO2009049304A1
(en)
*
|
2007-10-12 |
2009-04-16 |
Map Pharmaceuticals, Inc. |
Inhalation drug delivery
|
US9206233B2
(en)
|
2007-10-19 |
2015-12-08 |
University of Pittsburgh—of the Commonwealth System of Higher Education |
Templates for controlling synthesis of nanoparticles into discrete assemblies
|
US8785396B2
(en)
|
2007-10-24 |
2014-07-22 |
Mannkind Corporation |
Method and composition for treating migraines
|
US8642062B2
(en)
|
2007-10-31 |
2014-02-04 |
Abbott Cardiovascular Systems Inc. |
Implantable device having a slow dissolving polymer
|
US8039212B2
(en)
|
2007-11-05 |
2011-10-18 |
Celera Corporation |
Genetic polymorphisms associated with liver fibrosis, methods of detection and uses thereof
|
JP2011503232A
(ja)
|
2007-11-20 |
2011-01-27 |
ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド |
免疫応答の調節
|
US8598165B2
(en)
|
2007-11-26 |
2013-12-03 |
University Of Kansas |
Morpholines as selective inhibitors of cytochrome P450 2A13
|
BRPI0819883A2
(pt)
|
2007-11-28 |
2017-05-23 |
Sequoia Pharmaceuticals Inc |
composições e métodos para inibir citocromo p450 2d6
|
WO2009073215A1
(en)
|
2007-12-06 |
2009-06-11 |
Bend Research, Inc. |
Pharmaceutical compositions comprising nanoparticles and a resuspending material
|
EP2240162A4
(en)
|
2007-12-06 |
2013-10-09 |
Bend Res Inc |
NANOTE PARTICLES WITH A NON-IONIZABLE POLYMER AND AN AMIN-FUNCTIONALIZED METHACRYLATE COPOLYMER
|
KR100961880B1
(ko)
*
|
2007-12-12 |
2010-06-09 |
중앙대학교 산학협력단 |
밀링에 의한 기능성 약물나노입자의 제조방법 및 상기제조방법에 의해 입자 표면이 개질된 약물나노입자 제제
|
US20090238867A1
(en)
*
|
2007-12-13 |
2009-09-24 |
Scott Jenkins |
Nanoparticulate Anidulafungin Compositions and Methods for Making the Same
|
CA2707400A1
(en)
*
|
2007-12-14 |
2009-06-25 |
Amgen Inc. |
Method for treating bone fracture with anti-sclerostin antibodies
|
KR20100093129A
(ko)
|
2007-12-20 |
2010-08-24 |
노파르티스 아게 |
Pi 3 키나제 억제제로서 사용되는 티아졸 유도체
|
JP2011507906A
(ja)
*
|
2007-12-21 |
2011-03-10 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
フラビウイルス感染の治療に用いるための縮合5環式誘導体
|
US20100054981A1
(en)
*
|
2007-12-21 |
2010-03-04 |
Board Of Regents, The University Of Texas System |
Magnetic nanoparticles, bulk nanocomposite magnets, and production thereof
|
US9242295B2
(en)
|
2007-12-21 |
2016-01-26 |
The Univeristy Of Texas At Arlington |
Bulk nanocomposite magnets and methods of making bulk nanocomposite magnets
|
KR101405823B1
(ko)
*
|
2007-12-24 |
2014-06-12 |
주식회사 케이티앤지생명과학 |
녹내장의 치료 및 예방을 위한 약제 조성물
|
KR20090071829A
(ko)
*
|
2007-12-28 |
2009-07-02 |
주식회사 머젠스 |
신장질환의 치료 및 예방을 위한 약제 조성물
|
EP2234644B1
(en)
*
|
2008-01-04 |
2013-07-31 |
Biodel, Inc. |
Insulin formulations for insulin release as a function of tissue glucose levels
|
IL188647A0
(en)
*
|
2008-01-08 |
2008-11-03 |
Orina Gribova |
Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
|
US20090202649A1
(en)
*
|
2008-02-06 |
2009-08-13 |
Subhash Gore |
Fenofibrate formulations
|
WO2009101616A1
(en)
|
2008-02-11 |
2009-08-20 |
Ramot At Tel Aviv University Ltd. |
Novel conjugates for treating neurodegenerative diseases and disorders
|
US20090221620A1
(en)
|
2008-02-20 |
2009-09-03 |
Celera Corporation |
Gentic polymorphisms associated with stroke, methods of detection and uses thereof
|
EP2257160B1
(en)
|
2008-02-21 |
2017-07-05 |
Sequoia Pharmaceuticals, Inc. |
Diamide inhibitors of cytochrome p450
|
US20110009362A1
(en)
*
|
2008-02-27 |
2011-01-13 |
Dr. Reddy's Laboratories Ltd. |
Solubility-enhanced forms of aprepitant and pharmaceutical compositions thereof
|
CN101965195A
(zh)
|
2008-03-05 |
2011-02-02 |
巴克斯特国际公司 |
用于药物投送的组合物和方法
|
US8404850B2
(en)
*
|
2008-03-13 |
2013-03-26 |
Southwest Research Institute |
Bis-quaternary pyridinium-aldoxime salts and treatment of exposure to cholinesterase inhibitors
|
CA2715422A1
(en)
*
|
2008-03-21 |
2009-09-24 |
Elan Pharma International Limited |
Compositions for site-specific delivery of imatinib and methods of use
|
DK2271347T3
(en)
*
|
2008-03-28 |
2016-08-15 |
Hale Biopharma Ventures Llc |
Administration of benzodiazepine compositions
|
HU230862B1
(hu)
*
|
2008-04-28 |
2018-10-29 |
DARHOLDING Vagyonkezelő Kft |
Berendezés és eljárás nanorészecskék folyamatos üzemű előállítására
|
WO2009140341A2
(en)
*
|
2008-05-13 |
2009-11-19 |
Dr. Reddy's Laboratories Ltd. |
Atorvastatin compositions
|
US8173621B2
(en)
|
2008-06-11 |
2012-05-08 |
Gilead Pharmasset Llc |
Nucleoside cyclicphosphates
|
US20090311335A1
(en)
*
|
2008-06-12 |
2009-12-17 |
Scott Jenkins |
Combination of a triptan and an nsaid
|
EP3281663B8
(en)
|
2008-06-13 |
2022-09-21 |
MannKind Corporation |
Breath powered dry powder inhaler for drug delivery
|
US8485180B2
(en)
|
2008-06-13 |
2013-07-16 |
Mannkind Corporation |
Dry powder drug delivery system
|
GB2462022B
(en)
*
|
2008-06-16 |
2011-05-25 |
Biovascular Inc |
Controlled release compositions of agents that reduce circulating levels of platelets and methods thereof
|
BRPI0914308B8
(pt)
|
2008-06-20 |
2021-06-22 |
Mannkind Corp |
sistema de inalação
|
EP3093351B1
(en)
|
2008-07-09 |
2018-04-18 |
Celera Corporation |
Genetic polymorphisms associated with cardiovascular diseases, methods of detection and uses thereof
|
US20100151037A1
(en)
*
|
2008-08-07 |
2010-06-17 |
Yivan Jiang |
Method for the preparation of nanoparticles containing a poorly water-soluble pharmaceutically active compound
|
DE102008037025C5
(de)
|
2008-08-08 |
2016-07-07 |
Jesalis Pharma Gmbh |
Verfahren zur Herstellung kristalliner Wirkstoff-Mikropartikel bzw. einer Wirkstoffpartikel-Festkörperform
|
TWI614024B
(zh)
|
2008-08-11 |
2018-02-11 |
曼凱公司 |
超快起作用胰島素之用途
|
US8722706B2
(en)
*
|
2008-08-15 |
2014-05-13 |
Southwest Research Institute |
Two phase bioactive formulations of bis-quaternary pyridinium oxime sulfonate salts
|
EP2334378B1
(en)
|
2008-08-19 |
2014-04-09 |
XenoPort, Inc. |
Prodrugs of methyl hydrogen fumarate, pharmaceutical compositions thereof, and methods of use
|
US9700525B2
(en)
|
2008-08-20 |
2017-07-11 |
Board Of Supervisors Of Louisiana State University And Agricultural & Mechanical College |
Continuous local slow-release of therapeutics for head and neck problems and upper aerodigestive disorders
|
EP2373346B1
(en)
|
2008-09-10 |
2019-06-12 |
BioChemics, Inc. |
Ibuprofen for topical administration
|
CA2737543C
(en)
*
|
2008-09-19 |
2015-01-06 |
Activus Pharma Co., Ltd. |
Composite organic compound powder for medical use and production method and suspension of the same
|
TWI580441B
(zh)
*
|
2008-09-19 |
2017-05-01 |
愛爾康研究有限公司 |
穩定的藥學次微米懸浮液及其形成方法
|
GB0818403D0
(en)
*
|
2008-10-08 |
2008-11-12 |
Univ Leuven Kath |
Aqueous electrophoretic deposition
|
US8309134B2
(en)
*
|
2008-10-03 |
2012-11-13 |
Southwest Research Institute |
Modified calcium phosphate nanoparticle formation
|
EP2334845A2
(en)
*
|
2008-10-06 |
2011-06-22 |
Katholieke Universiteit Leuven K.U. Leuven R&D |
Functional layers of biomolecules and living cells, and a novel system to produce such
|
US20100098770A1
(en)
*
|
2008-10-16 |
2010-04-22 |
Manikandan Ramalingam |
Sirolimus pharmaceutical formulations
|
US8277697B2
(en)
*
|
2008-10-29 |
2012-10-02 |
Global Oled Technology Llc |
Color filter element with improved colorant dispersion
|
US20100160369A1
(en)
|
2008-12-04 |
2010-06-24 |
Exelixis, Inc. |
S1P1 Agonists and Methods of Making And Using
|
CA2746887C
(en)
*
|
2008-12-15 |
2016-07-05 |
Banner Pharmacaps, Inc. |
Methods for enhancing the release and absorption of water insoluble active agents
|
JP2012512255A
(ja)
|
2008-12-17 |
2012-05-31 |
アムジエン・インコーポレーテツド |
ホスホジエステラーゼ10阻害剤としてのアミノピリジンおよびカルボキシピリジン化合物
|
PA8855801A1
(es)
|
2008-12-23 |
2010-07-27 |
|
Sintesis de nucleosidos de purina
|
EP2376514A2
(en)
|
2008-12-23 |
2011-10-19 |
Pharmasset, Inc. |
Nucleoside analogs
|
AR074897A1
(es)
|
2008-12-23 |
2011-02-23 |
Pharmasset Inc |
Fosforamidatos de nucleosidos
|
US20100159010A1
(en)
*
|
2008-12-24 |
2010-06-24 |
Mutual Pharmaceutical Company, Inc. |
Active Agent Formulations, Methods of Making, and Methods of Use
|
US8314106B2
(en)
|
2008-12-29 |
2012-11-20 |
Mannkind Corporation |
Substituted diketopiperazine analogs for use as drug delivery agents
|
AU2009334794B2
(en)
|
2009-01-02 |
2014-12-04 |
Bgp Products Ireland Limited |
Novel use of fibrates
|
US20110268775A1
(en)
|
2009-01-06 |
2011-11-03 |
Pharmanova, Inc. |
Nanoparticle pharmaceutical formulations
|
US11304960B2
(en)
|
2009-01-08 |
2022-04-19 |
Chandrashekar Giliyar |
Steroidal compositions
|
WO2010085641A1
(en)
|
2009-01-22 |
2010-07-29 |
Noramco, Inc. |
Process for preparing particles of opioids and compositions produced thereby
|
AR075180A1
(es)
*
|
2009-01-29 |
2011-03-16 |
Novartis Ag |
Formulaciones orales solidas de una pirido-pirimidinona
|
AU2010208880A1
(en)
|
2009-01-30 |
2011-08-18 |
Meiji Seika Pharma Co., Ltd. |
Finely pulverized pharmaceutical composition
|
US8236862B2
(en)
*
|
2009-02-06 |
2012-08-07 |
University Of Southern California |
Therapeutic compositions comprising monoterpenes
|
WO2010091164A1
(en)
|
2009-02-06 |
2010-08-12 |
Exelixis, Inc. |
Inhibitors of glucosylceramide synthase
|
WO2010091104A1
(en)
|
2009-02-06 |
2010-08-12 |
Exelixis, Inc. |
Glucosylceramide synthase inhibitors
|
US20100204265A1
(en)
*
|
2009-02-09 |
2010-08-12 |
Genelabs Technologies, Inc. |
Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
|
EP2398791A1
(en)
|
2009-02-18 |
2011-12-28 |
Amgen, Inc |
INDOLE/BENZIMIDAZOLE COMPOUNDS AS mTOR KINASE INHIBITORS
|
WO2010097115A1
(en)
|
2009-02-26 |
2010-09-02 |
Glaxo Group Limited |
Pharmaceutical formulations comprising 4-{(1r)-2- [(6-{2-[(2,6-dichlorobenzyl)oxy] ethoxy}hexyl)amino]-1-hydroxyethyl}-2- (hydroxymethyl)phenol
|
US9060927B2
(en)
*
|
2009-03-03 |
2015-06-23 |
Biodel Inc. |
Insulin formulations for rapid uptake
|
WO2010105094A1
(en)
|
2009-03-11 |
2010-09-16 |
Mannkind Corporation |
Apparatus, system and method for measuring resistance of an inhaler
|
WO2010110931A2
(en)
|
2009-03-23 |
2010-09-30 |
The Brigham And Women's Hospital, Inc. |
Glycoconjugate vaccines
|
US7828996B1
(en)
|
2009-03-27 |
2010-11-09 |
Abbott Cardiovascular Systems Inc. |
Method for the manufacture of stable, nano-sized particles
|
US20100249071A1
(en)
|
2009-03-30 |
2010-09-30 |
Exelixis, Inc. |
Modulators of S1P and Methods of Making And Using
|
WO2010114770A1
(en)
*
|
2009-03-30 |
2010-10-07 |
Cerulean Pharma Inc. |
Polymer-agent conjugates, particles, compositions, and related methods of use
|
AU2010234339B2
(en)
*
|
2009-04-09 |
2014-06-26 |
Alkermes Pharma Ireland Limited |
Drug delivery composition
|
US20100268187A1
(en)
*
|
2009-04-17 |
2010-10-21 |
Ranbaxy Laboratories Limited |
Packaging for sirolimus and composition thereof
|
CN106420667A
(zh)
|
2009-04-24 |
2017-02-22 |
伊休蒂卡有限公司 |
双氯芬酸的新剂型
|
WO2010121328A1
(en)
|
2009-04-24 |
2010-10-28 |
Iceutica Pty Ltd |
A novel formulation of indomethacin
|
US10952965B2
(en)
*
|
2009-05-15 |
2021-03-23 |
Baxter International Inc. |
Compositions and methods for drug delivery
|
US20100291221A1
(en)
*
|
2009-05-15 |
2010-11-18 |
Robert Owen Cook |
Method of administering dose-sparing amounts of formoterol fumarate-budesonide combination particles by inhalation
|
EP2253306A1
(en)
|
2009-05-18 |
2010-11-24 |
Royal College of Surgeons in Ireland |
Orodispersible dosage forms containing solid drug dispersions
|
ES2649112T3
(es)
|
2009-05-18 |
2018-01-10 |
Sigmoid Pharma Limited |
Composición que comprende gotas de aceite
|
TWI583692B
(zh)
|
2009-05-20 |
2017-05-21 |
基利法瑪席特有限責任公司 |
核苷磷醯胺
|
WO2010135568A1
(en)
|
2009-05-22 |
2010-11-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of mtor and their use to treat cancer
|
WO2010135714A2
(en)
|
2009-05-22 |
2010-11-25 |
The Methodist Hospital Research Institute |
Methods for modulating adipocyte expression using microrna compositions
|
FR2945950A1
(fr)
|
2009-05-27 |
2010-12-03 |
Elan Pharma Int Ltd |
Compositions de nanoparticules anticancereuses et procedes pour les preparer
|
TWI558422B
(zh)
|
2009-05-27 |
2016-11-21 |
阿艾克麥斯製藥愛爾蘭有限公司 |
減少奈米顆粒活性劑組成物中薄片狀聚集之技術
|
TR200904500A2
(tr)
|
2009-06-10 |
2009-10-21 |
Öner Levent |
Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
|
JP5760295B2
(ja)
|
2009-06-12 |
2015-08-05 |
シナプサス セラピューティクス,インコーポレーテッド |
舌下用アポモルフィン
|
WO2010144789A2
(en)
|
2009-06-12 |
2010-12-16 |
Mannkind Corporation |
Diketopiperazine microparticles with defined specific surface areas
|
RU2012101214A
(ru)
|
2009-06-16 |
2013-07-27 |
Пфайзер Инк. |
Лекарственные формы апиксабана
|
US9149024B2
(en)
|
2009-06-22 |
2015-10-06 |
Massachusetts Eye & Ear Infirmary |
Islet1 (Isl1) and hearing loss
|
US8293753B2
(en)
|
2009-07-02 |
2012-10-23 |
Novartis Ag |
Substituted 2-carboxamide cycloamino ureas
|
US20110003000A1
(en)
*
|
2009-07-06 |
2011-01-06 |
Femmepharma Holding Company, Inc. |
Transvaginal Delivery of Drugs
|
WO2011004376A1
(en)
|
2009-07-09 |
2011-01-13 |
Oshadi Drug Administration Ltd. |
Matrix carrier compositions, methods and uses
|
US20130029970A1
(en)
|
2009-07-10 |
2013-01-31 |
Ironwood Pharmaceuticals, Inc |
CB Receptor Agonists
|
EP2283824B1
(en)
|
2009-07-30 |
2017-04-19 |
Special Products Line S.p.A. |
Compositions and formulations based on swellable matrices for sustained release of poorly soluble drugs such as clarithromycin
|
AR077692A1
(es)
|
2009-08-06 |
2011-09-14 |
Vitae Pharmaceuticals Inc |
Sales de 2-((r)-(3-clorofenil) ((r)-1-((s) -2-(metilamino)-3-((r)-tetrahidro-2h-piran-3-il) propilcarbamoil) piperidin -3-il) metoxi) etilcarbamato de metilo
|
UA108618C2
(uk)
|
2009-08-07 |
2015-05-25 |
|
Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
|
WO2011018504A2
(en)
|
2009-08-12 |
2011-02-17 |
Sigmoid Pharma Limited |
Immunomodulatory compositions comprising a polymer matrix and an oil phase
|
EP2298296A1
(en)
|
2009-08-25 |
2011-03-23 |
CNRS Centre National De La Recherche Scientifique |
Composition and method for treating cognitive impairments in down syndrome subjects
|
WO2011025905A1
(en)
|
2009-08-28 |
2011-03-03 |
Research Development Foundation |
Urocortin 2 analogs and uses thereof
|
US9775819B2
(en)
*
|
2009-09-16 |
2017-10-03 |
R.P. Scherer Technologies, Llc |
Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin
|
UY32919A
(es)
|
2009-10-02 |
2011-04-29 |
Boehringer Ingelheim Int |
Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, mé todos para su tratamiento y sus usos
|
US8883748B2
(en)
*
|
2009-10-16 |
2014-11-11 |
Lifecare Innovations Pvt. Ltd. |
Formulation for treating fungal infection
|
JP5965319B2
(ja)
|
2009-10-22 |
2016-08-03 |
エイピーアイ・ジェネシス,エルエルシー |
フラボノイド含有組成物の製造方法及び使用
|
WO2011056889A1
(en)
|
2009-11-03 |
2011-05-12 |
Mannkind Corporation |
An apparatus and method for simulating inhalation efforts
|
EP2496231A1
(en)
|
2009-11-05 |
2012-09-12 |
Lexicon Pharmaceuticals, Inc. |
Tryptophan hydroxylase inhibitors for the treatment of cancer
|
US9023886B2
(en)
*
|
2009-11-10 |
2015-05-05 |
Celgene Corporation |
Nanosuspension of a poorly soluble drug via microfluidization process
|
GB0921075D0
(en)
|
2009-12-01 |
2010-01-13 |
Glaxo Group Ltd |
Novel combination of the therapeutic agents
|
PT2965749T
(pt)
|
2009-12-03 |
2018-10-09 |
Novartis Ag |
Supensões de nanopartículas contendo um polímero de carboxivinilo
|
WO2011070579A1
(en)
*
|
2009-12-09 |
2011-06-16 |
Biolinerx Ltd. |
Methods of improving cognitive functions
|
WO2011071565A1
(en)
|
2009-12-11 |
2011-06-16 |
Exelixis, Inc. |
Tgr5 agonists
|
WO2011075636A2
(en)
|
2009-12-18 |
2011-06-23 |
Amgen Inc. |
Wise binding agents and epitopes
|
CA2785253A1
(en)
|
2009-12-22 |
2011-06-30 |
Leo Pharma A/S |
Calcipotriol monohydrate nanocrystals
|
JP5731538B2
(ja)
|
2009-12-23 |
2015-06-10 |
アイアンウッド ファーマシューティカルズ インコーポレイテッド |
Crth2モジュレーター
|
MX2012008790A
(es)
|
2010-01-27 |
2012-08-17 |
Glaxosmithkline Biolog Sa |
Antigenos de tuberculosis modificados.
|
US9028873B2
(en)
*
|
2010-02-08 |
2015-05-12 |
Southwest Research Institute |
Nanoparticles for drug delivery to the central nervous system
|
UY33221A
(es)
|
2010-02-09 |
2011-09-30 |
Univ California |
MÉTODOS PARA TRATAR CÁNCER USANDO INHIBIDORES DE PI3K Y mTOR EN COMBINACIÓN CON INHIBIDORES DE AUTOFAGIA
|
WO2011100324A1
(en)
|
2010-02-09 |
2011-08-18 |
Ironwood Pharmaceuticals Inc. |
Cannabinoid receptor agonists
|
US20130178453A1
(en)
|
2010-02-09 |
2013-07-11 |
Ironwood Pharmaceuticals, Inc. |
Cannabinoid Agonists
|
CN102753168A
(zh)
|
2010-02-10 |
2012-10-24 |
莱西肯医药有限公司 |
用于治疗转移性骨病的色氨酸羟化酶抑制剂
|
JP2013519732A
(ja)
|
2010-02-17 |
2013-05-30 |
アムジエン・インコーポレーテツド |
疼痛治療のためのナトリウムチャンネル阻害薬としてのアリールカルボキサミド誘導体
|
WO2011101429A1
(en)
|
2010-02-22 |
2011-08-25 |
F. Hoffmann-La Roche Ag |
Pyrido[3,2-d]pyrimidine pi3k delta inhibitor compounds and methods of use
|
MX2012009821A
(es)
*
|
2010-02-24 |
2012-10-09 |
Univ Ramot |
Formas cristalinas de la sal de tri-mesilato de perfenazina-gaba y proceso para producirlas.
|
CN102791368B
(zh)
*
|
2010-03-11 |
2015-11-25 |
浜松光子学株式会社 |
微粒子分散液制造方法和微粒子分散液制造装置
|
CA2793241C
(en)
|
2010-03-22 |
2020-07-14 |
Bio-Synectics Inc. |
Method for preparing nano-particles
|
PL3290428T3
(pl)
|
2010-03-31 |
2022-02-07 |
Gilead Pharmasset Llc |
Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu
|
US8859756B2
(en)
|
2010-03-31 |
2014-10-14 |
Gilead Pharmasset Llc |
Stereoselective synthesis of phosphorus containing actives
|
UY33312A
(es)
|
2010-03-31 |
2011-10-31 |
Pharmasset Inc |
Fosforamidato de nucleosido de purina
|
DE102010003711B4
(de)
|
2010-04-08 |
2015-04-09 |
Jesalis Pharma Gmbh |
Verfahren zur Herstellung kristalliner Wirkstoffpartikel
|
US20110269735A1
(en)
|
2010-04-19 |
2011-11-03 |
Celera Corporation |
Genetic polymorphisms associated with statin response and cardiovascular diseases, methods of detection and uses thereof
|
ES2911185T3
(es)
|
2010-04-23 |
2022-05-18 |
Univ Florida |
Composiciones de rAAV-guanilato ciclasa y métodos para tratar la amaurosis congénita de Leber 1 (LCA1)
|
WO2011135580A2
(en)
|
2010-04-28 |
2011-11-03 |
Cadila Healthcare Limited |
Pharmaceutical compositions of sirolimus
|
US20130116333A1
(en)
*
|
2010-05-05 |
2013-05-09 |
Ratiopharm Gmbh |
Solid tapentadol in non-crystalline form
|
US8765737B1
(en)
|
2010-05-11 |
2014-07-01 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
US9394294B2
(en)
|
2010-05-11 |
2016-07-19 |
Demerx, Inc. |
Methods and compositions for preparing and purifying noribogaine
|
US8362007B1
(en)
|
2010-05-11 |
2013-01-29 |
Demerx, Inc. |
Substituted noribogaine
|
EP2569300A1
(en)
|
2010-05-13 |
2013-03-20 |
Amgen Inc. |
Nitrogen heterocyclic compounds useful as pde10 inhibitors
|
JP2013526546A
(ja)
|
2010-05-13 |
2013-06-24 |
アムジエン・インコーポレーテツド |
Pde10阻害剤としてのヘテロアリ−ルオキシヘテロシクリル化合物
|
WO2011143366A1
(en)
|
2010-05-13 |
2011-11-17 |
Amgen Inc. |
Heteroaryloxycarbocyclyl compounds as pde10 inhibitors
|
AU2011253143A1
(en)
|
2010-05-13 |
2012-12-06 |
Amgen Inc. |
Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
|
KR101861867B1
(ko)
|
2010-05-14 |
2018-05-29 |
암젠 인크 |
고농도의 항체 제제
|
US9012511B2
(en)
|
2010-05-19 |
2015-04-21 |
Alkermes Pharma Ireland Limited |
Nanoparticulate cinacalcet compositions
|
HUP1000325A2
(en)
|
2010-06-18 |
2012-01-30 |
Druggability Technologies Ip Holdco Jersey Ltd |
Nanostructured aprepitant compositions and process for their preparation
|
AU2011271097B2
(en)
|
2010-06-21 |
2014-11-27 |
Mannkind Corporation |
Dry powder drug delivery system and methods
|
US9586954B2
(en)
|
2010-06-22 |
2017-03-07 |
Demerx, Inc. |
N-substituted noribogaine prodrugs
|
US8741891B1
(en)
|
2010-06-22 |
2014-06-03 |
Demerx, Inc. |
N-substituted noribogaine prodrugs
|
US8637648B1
(en)
|
2010-06-22 |
2014-01-28 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
US8802832B2
(en)
|
2010-06-22 |
2014-08-12 |
Demerx, Inc. |
Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
|
WO2012012147A2
(en)
|
2010-06-30 |
2012-01-26 |
Victoria Link Ltd |
Methods and compositions for treatment of multiple sclerosis
|
AR084469A1
(es)
|
2010-07-09 |
2013-05-22 |
Exelixis Inc |
Combinaciones de inhibidores de quinasas para el tratamiento del cancer
|
US20130216552A1
(en)
|
2010-07-12 |
2013-08-22 |
Ironwood Pharmaceuticals, Inc. |
Crth2 modulators
|
WO2012009134A1
(en)
|
2010-07-12 |
2012-01-19 |
Ironwood Pharmaceuticals, Inc. |
Crth2 modulators
|
JP6049615B2
(ja)
|
2010-07-23 |
2016-12-21 |
デマークス・インコーポレイテッドDemerx,Inc. |
ノリボガイン組成物
|
US10449177B2
(en)
|
2010-08-19 |
2019-10-22 |
Buck Institute For Research On Aging |
Methods of treating mild cognitive impairment (MCI) and related disorders
|
EP2616443A1
(en)
|
2010-09-14 |
2013-07-24 |
Exelixis, Inc. |
Phtalazine derivatives as jak1 inhibitors
|
JP5792819B2
(ja)
|
2010-09-14 |
2015-10-14 |
エクセリクシス, インク. |
Pi3k−デルタの阻害剤ならびにそれらの使用法および製造法
|
TWI617560B
(zh)
|
2010-09-14 |
2018-03-11 |
伊塞利克斯公司 |
PI3Kδ 抑制劑以及其應用和生產方法
|
US8916610B2
(en)
|
2010-09-22 |
2014-12-23 |
Ramot At Tel-Aviv University Ltd. |
Acid addition salt of a nortriptyline-GABA conjugate and a process of preparing same
|
BR112013006651A2
(pt)
|
2010-09-23 |
2017-07-18 |
Nuformix Ltd |
composição e cocristal de aprepitante l-prolina
|
JP2013540759A
(ja)
|
2010-09-27 |
2013-11-07 |
エクセリクシス, インク. |
去勢抵抗性前立腺癌および造骨性転移の治療のためのmetおよびvegfの二元阻害薬
|
US20140057908A1
(en)
|
2010-09-27 |
2014-02-27 |
Exelixis, Inc. |
Method of Treating Cancer
|
WO2012044572A1
(en)
|
2010-09-27 |
2012-04-05 |
Exelixis, Inc. |
Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
|
WO2012051426A2
(en)
*
|
2010-10-15 |
2012-04-19 |
Glaxo Group Limited |
Aggregate nanoparticulate medicament formulations, manufacture and use thereof
|
WO2012061337A1
(en)
|
2010-11-02 |
2012-05-10 |
Exelixis, Inc. |
Fgfr2 modulators
|
EP2635260A4
(en)
*
|
2010-11-02 |
2014-07-09 |
Univ Nebraska |
COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS
|
US20120108651A1
(en)
|
2010-11-02 |
2012-05-03 |
Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL) |
Genetic polymorphisms associated with venous thrombosis and statin response, methods of detection and uses thereof
|
WO2012065057A2
(en)
|
2010-11-12 |
2012-05-18 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors and methods of their use
|
WO2012065019A2
(en)
|
2010-11-12 |
2012-05-18 |
Exelixis, Inc. |
Pyridopyrimidinone inhibitors of p13k alpha
|
EP2640367A2
(en)
|
2010-11-15 |
2013-09-25 |
Exelixis, Inc. |
Benzoxazepines as inhibitors of pi3k/mtor and methods of their use and manufacture
|
US20140080810A1
(en)
|
2010-11-15 |
2014-03-20 |
Exelixis, Inc. |
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
|
US20140378436A9
(en)
|
2010-11-24 |
2014-12-25 |
Exelixis, Inc. |
Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their use and Manufacture
|
GB201020032D0
(en)
|
2010-11-25 |
2011-01-12 |
Sigmoid Pharma Ltd |
Composition
|
ES2716158T3
(es)
|
2010-11-30 |
2019-06-10 |
Gilead Pharmasset Llc |
2'-spiro-nucleótidos para el tratamiento de hepatitis C
|
US9358241B2
(en)
|
2010-11-30 |
2016-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US9034858B2
(en)
|
2010-11-30 |
2015-05-19 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
US20180153904A1
(en)
|
2010-11-30 |
2018-06-07 |
Lipocine Inc. |
High-strength testosterone undecanoate compositions
|
AU2011338389A1
(en)
|
2010-12-09 |
2013-06-13 |
Amgen Inc. |
Bicyclic compounds as Pim inhibitors
|
US20120148675A1
(en)
|
2010-12-10 |
2012-06-14 |
Basawaraj Chickmath |
Testosterone undecanoate compositions
|
EA031156B1
(ru)
|
2010-12-16 |
2018-11-30 |
Суновион Фармасьютикалз Инк. |
Сублингвальные пленки
|
US9351989B2
(en)
|
2010-12-29 |
2016-05-31 |
Inhibitex, Inc. |
Substituted purine nucleosides, phosphoroamidate and phosphorodiamidate derivatives for treatment of viral infections
|
EP2661434A4
(en)
|
2011-01-06 |
2014-07-09 |
Beta Pharma Canada Inc |
NEW URGES FOR THE TREATMENT AND PREVENTION OF CANCER
|
EP2481740B1
(en)
|
2011-01-26 |
2015-11-04 |
DemeRx, Inc. |
Methods and compositions for preparing noribogaine from voacangine
|
CN103649118A
(zh)
|
2011-03-01 |
2014-03-19 |
安进公司 |
双特异性结合剂
|
EP2688886A1
(en)
|
2011-03-22 |
2014-01-29 |
Amgen Inc. |
Azole compounds as pim inhibitors
|
CR20160147A
(es)
|
2011-03-25 |
2016-08-03 |
Amgen Inc |
Formulaciones de anticuerpos
|
EP2694402B1
(en)
|
2011-04-01 |
2017-03-22 |
MannKind Corporation |
Blister package for pharmaceutical cartridges
|
JP6161593B2
(ja)
|
2011-04-15 |
2017-07-12 |
ヤンセン ファーマシューティカ エヌ.ベー. |
凍結乾燥された薬物ナノ懸濁物
|
US8883497B2
(en)
|
2011-04-28 |
2014-11-11 |
University Of Southern California |
Human myeloid derived suppressor cell cancer markers
|
EP2702063A1
(en)
|
2011-04-29 |
2014-03-05 |
Amgen Inc. |
Bicyclic pyridazine compounds as pim inhibitors
|
AU2012249500A1
(en)
|
2011-04-29 |
2013-11-28 |
Exelixis, Inc. |
Method of treating lymphoma using pyridopyrimidinone inhibitors of PI3K/MTOR
|
WO2012154879A2
(en)
|
2011-05-09 |
2012-11-15 |
Van Andel Research Institute |
Autophagy inhibitors
|
US8709034B2
(en)
|
2011-05-13 |
2014-04-29 |
Broncus Medical Inc. |
Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
|
WO2012158530A1
(en)
|
2011-05-13 |
2012-11-22 |
Broncus Technologies, Inc. |
Methods and devices for ablation of tissue
|
JP5974084B2
(ja)
|
2011-05-17 |
2016-08-23 |
プリンシピア バイオファーマ インコーポレイテッド |
チロシンキナーゼ阻害剤
|
WO2012158810A1
(en)
|
2011-05-17 |
2012-11-22 |
Principia Biopharma Inc. |
Tyrosine kinase inhibitors
|
EP2710006A1
(en)
|
2011-05-17 |
2014-03-26 |
Principia Biopharma Inc. |
Azaindole derivatives as tyrosine kinase inhibitors
|
US9376438B2
(en)
|
2011-05-17 |
2016-06-28 |
Principia Biopharma, Inc. |
Pyrazolopyrimidine derivatives as tyrosine kinase inhibitors
|
PL3415139T3
(pl)
|
2011-06-14 |
2022-07-11 |
Neurelis, Inc. |
Podawanie benzodiazepiny
|
WO2012174472A1
(en)
|
2011-06-17 |
2012-12-20 |
Mannkind Corporation |
High capacity diketopiperazine microparticles
|
WO2012177595A1
(en)
|
2011-06-21 |
2012-12-27 |
Oncofactor Corporation |
Compositions and methods for the therapy and diagnosis of cancer
|
JP5978296B2
(ja)
|
2011-06-28 |
2016-08-24 |
フジアン・ミンドン・レジュヴネイション・ファーマスーティカル・カンパニー・リミテッド |
抗アレルギ性ベンゾシクロヘプタチオフェン誘導体
|
WO2013012649A1
(en)
|
2011-07-15 |
2013-01-24 |
Glaxosmithkline Llc |
Azaindole compounds and methods for treating hiv
|
HUE032747T2
(en)
|
2011-07-22 |
2017-10-30 |
Chemocentryx Inc |
Crystalline form of the sodium salt of 4-tert-butyl-N- [4-chloro-2- (1-oxypyridine-4-carbonyl) phenyl] benzenesulfonamide
|
RU2607191C2
(ru)
|
2011-07-22 |
2017-01-10 |
Хемоцентрикс, Инк. |
Полиморфные формы натриевой соли 4-трет-бутил-n-[4-хлор-2-(1-окси-пиридин-4-карбонил)-фенил]-бензолсульфонамида
|
MX355816B
(es)
|
2011-08-04 |
2018-05-02 |
Amgen Inc |
Metodo para tratar los defectos de espacio oseo.
|
US9617274B1
(en)
|
2011-08-26 |
2017-04-11 |
Demerx, Inc. |
Synthetic noribogaine
|
PE20141411A1
(es)
|
2011-09-01 |
2014-10-29 |
Glaxo Group Ltd |
Nueva forma de cristal
|
WO2013040337A1
(en)
|
2011-09-14 |
2013-03-21 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors for the treatment of cancer
|
KR101794032B1
(ko)
|
2011-09-21 |
2017-11-07 |
(주)바이오시네틱스 |
나노입자 제조방법
|
MX351133B
(es)
|
2011-09-22 |
2017-10-03 |
Exelixis Inc |
Metodo para tratar osteoporosis.
|
ES2632443T3
(es)
|
2011-09-22 |
2017-09-13 |
Viiv Healthcare Uk Limited |
Compuestos de pirrolopiridinona y procedimientos de tratamiento del VIH
|
KR102162901B1
(ko)
|
2011-09-29 |
2020-10-08 |
피엘엑스 옵코 인코포레이티드 |
위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법
|
WO2013056067A1
(en)
|
2011-10-13 |
2013-04-18 |
Exelixis, Inc. |
Compounds for use in the treatment of basal cell carcinoma
|
TWI580442B
(zh)
*
|
2011-10-19 |
2017-05-01 |
傑特大學 |
醫藥毫微懸浮物
|
CA2852536A1
(en)
|
2011-10-24 |
2013-05-02 |
Mannkind Corporation |
Methods and compositions for treating pain
|
KR20140096083A
(ko)
|
2011-11-01 |
2014-08-04 |
엑셀리시스, 인코포레이티드 |
림프증식성 악성종양의 치료를 위한 포스파티딜이노시톨 3-키나아제 저해제로서 n(3{[(3{[2클로로5(메톡시)페닐]아미노}퀴녹살린2일)아미노]설포닐}페닐)2메틸알라닌아미드
|
WO2013067306A1
(en)
|
2011-11-02 |
2013-05-10 |
Exelixis, Inc. |
Phosphatidylinositol 3-kinase inhibitors for the treatment of childhood cancers
|
EP2776033A1
(en)
|
2011-11-08 |
2014-09-17 |
Exelixis, Inc. |
Dual inhibitor of met and vegf for treating cancer
|
CN104039226A
(zh)
|
2011-11-08 |
2014-09-10 |
埃克塞里艾克西斯公司 |
定量癌症治疗的方法
|
MX359234B
(es)
|
2011-11-11 |
2018-09-20 |
Hutchinson Fred Cancer Res |
Inmunoterapia de celulas t objetivadas en ciclina a1 para cancer.
|
EP2780009A4
(en)
|
2011-11-17 |
2015-05-06 |
Univ Colorado Regents |
METHODS AND COMPOSITIONS FOR ENHANCED IL-MEDICATION ADMINISTRATION AND EXTENDED DELIVERY FORMULATIONS
|
WO2013078235A1
(en)
|
2011-11-23 |
2013-05-30 |
Broncus Medical Inc |
Methods and devices for diagnosing, monitoring, or treating medical conditions through an opening through an airway wall
|
CN104159584A
(zh)
|
2011-11-25 |
2014-11-19 |
诺弗米克斯有限公司 |
阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
|
WO2013085922A1
(en)
|
2011-12-09 |
2013-06-13 |
Demerx, Inc. |
Phosphate esters of noribogaine
|
JO3387B1
(ar)
|
2011-12-16 |
2019-03-13 |
Glaxosmithkline Llc |
مشتقات بيتولين
|
MX354270B
(es)
|
2011-12-28 |
2018-02-21 |
Amgen Inc |
Uso de un anticuerpo antiesclerostina en el tratamiento de la pérdida ósea alveolar. .
|
US9150584B2
(en)
|
2012-01-25 |
2015-10-06 |
Demerx, Inc. |
Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
|
US8877921B2
(en)
|
2012-01-25 |
2014-11-04 |
Demerx, Inc. |
Synthetic voacangine
|
TW201348226A
(zh)
|
2012-02-28 |
2013-12-01 |
Amgen Inc |
作為pim抑制劑之醯胺
|
TW201348231A
(zh)
|
2012-02-29 |
2013-12-01 |
Amgen Inc |
雜雙環化合物
|
KR102236462B1
(ko)
|
2012-03-19 |
2021-04-08 |
시다라 세라퓨틱스, 인코포레이티드 |
에키노칸딘 계열의 화합물에 대한 투여 용법
|
KR20140139563A
(ko)
|
2012-03-22 |
2014-12-05 |
나노테라퓨틱스, 인코포레이티드 |
캡슐화된 디에틸렌트리아민펜타아세테이트 입자들의 경구 전달을 위한 조성물 및 방법
|
KR101956586B1
(ko)
*
|
2012-03-27 |
2019-03-11 |
일양약품주식회사 |
약제학적 조성물 및 이의 제조방법
|
WO2013148978A1
(en)
|
2012-03-30 |
2013-10-03 |
Lexicon Pharmaceuticals, Inc. |
Methods and compositions for the treatment of necrotizing enterocolitis
|
WO2013155422A1
(en)
|
2012-04-12 |
2013-10-17 |
Ironwood Pharmaceuticals, Inc. |
Methods of treating alopecia and acne
|
US9452107B2
(en)
|
2012-04-16 |
2016-09-27 |
New Jersey Institute Of Technology |
Systems and methods for superdisintegrant-based composite particles for dispersion and dissolution of agents
|
JP2015515988A
(ja)
|
2012-05-02 |
2015-06-04 |
エクセリクシス, インク. |
溶骨性骨転移を治療するためのmet−vegf二重調節剤
|
CA2871745C
(en)
|
2012-05-03 |
2023-01-24 |
Kala Pharmaceuticals, Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
US11596599B2
(en)
|
2012-05-03 |
2023-03-07 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
US9827191B2
(en)
|
2012-05-03 |
2017-11-28 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
KR102310775B1
(ko)
|
2012-05-03 |
2021-10-07 |
칼라 파마슈티컬스, 인크. |
개선된 점막 수송을 나타내는 제약 나노입자
|
CA2867236C
(en)
|
2012-05-11 |
2017-02-28 |
Activus Pharma Co., Ltd. |
Organic compound nano-powder, method for producing the same and suspension
|
EP2849776B1
(en)
|
2012-05-17 |
2021-04-21 |
vTv Therapeutics LLC |
Glucokinase activator compositions for the treatment of diabetes
|
CN104736178A
(zh)
|
2012-06-04 |
2015-06-24 |
药品循环公司 |
布鲁顿酪氨酸激酶抑制剂的晶形
|
AR091436A1
(es)
|
2012-06-14 |
2015-02-04 |
Amgen Inc |
Compuestos de azetidina y piperidina utiles como inhibidores de pde10
|
CA2914782C
(en)
|
2012-06-21 |
2021-05-25 |
Phosphorex, Inc. |
Nanoparticles of indirubin, derivatives thereof and methods of making and using same
|
GB201212010D0
(en)
|
2012-07-05 |
2012-08-22 |
Sigmoid Pharma Ltd |
Formulations
|
CN104619342A
(zh)
|
2012-07-05 |
2015-05-13 |
Ucb医药有限公司 |
骨疾病的治疗
|
US9163023B2
(en)
|
2012-07-12 |
2015-10-20 |
Viiv Healthcare Uk Limited |
Compounds and methods for treating HIV
|
WO2014012069A2
(en)
|
2012-07-12 |
2014-01-16 |
Mannkind Corporation |
Dry powder drug delivery systems and methods
|
JOP20130213B1
(ar)
|
2012-07-17 |
2021-08-17 |
Takeda Pharmaceuticals Co |
معارضات لمستقبلht3-5
|
WO2014022752A1
(en)
|
2012-08-03 |
2014-02-06 |
Amgen Inc. |
Macrocycles as pim inhibitors
|
EP2882722B1
(en)
|
2012-08-13 |
2016-07-27 |
Takeda Pharmaceutical Company Limited |
Quinoxaline derivatives as gpr6 modulators
|
CA2882713A1
(en)
|
2012-08-22 |
2014-02-27 |
Xenoport, Inc. |
Methods of administering monomethyl fumarate and prodrugs thereof having reduced side effects
|
WO2014031894A1
(en)
|
2012-08-22 |
2014-02-27 |
Xenoport, Inc. |
Oral dosage forms of methyl hydrogen fumarate and prodrugs thereof
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
WO2014036528A2
(en)
|
2012-08-31 |
2014-03-06 |
Ixchel Pharma, Llc |
Agents useful for treating obesity, diabetes and related disorders
|
JP2015526520A
(ja)
|
2012-08-31 |
2015-09-10 |
プリンシピア バイオファーマ インコーポレイテッド |
Itk阻害剤としてのベンズイミダゾール誘導体
|
PT3181567T
(pt)
|
2012-09-10 |
2019-06-24 |
Principia Biopharma Inc |
Compostos de pirazolopirimidina como inibidores de cinase
|
EP2911690A1
(en)
|
2012-10-26 |
2015-09-02 |
MannKind Corporation |
Inhalable influenza vaccine compositions and methods
|
WO2014081732A1
(en)
|
2012-11-20 |
2014-05-30 |
Principia Biopharma Inc. |
Azaindole derivatives as jak3 inhibitors
|
UY35148A
(es)
|
2012-11-21 |
2014-05-30 |
Amgen Inc |
Immunoglobulinas heterodiméricas
|
EP2925764B1
(en)
|
2012-11-30 |
2023-03-01 |
Sanford-Burnham Medical Research Institute |
Inhibitor of apoptosis protein (iap) antagonists
|
WO2014091318A1
(en)
|
2012-12-11 |
2014-06-19 |
Lupin Atlantis Holdings, S.A. |
Reduced dose pharmaceutical compositions of fenofibrate
|
WO2014100021A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
|
US9045481B2
(en)
|
2012-12-20 |
2015-06-02 |
Demerx, Inc. |
Substituted noribogaine
|
JP2016508979A
(ja)
|
2012-12-20 |
2016-03-24 |
デメレックス, インコーポレイテッド |
置換ノルイボガイン
|
US8940728B2
(en)
|
2012-12-20 |
2015-01-27 |
Demerx, Inc. |
Substituted noribogaine
|
EP2951205B1
(en)
|
2013-02-01 |
2021-08-11 |
Santa Maria Biotherapeutics, Inc. |
Anti-activin-a compounds for the treatment of ovarian cancer
|
CN105121023B
(zh)
*
|
2013-02-28 |
2017-08-25 |
太阳化学公司 |
用于在液体分散液中制造研磨的固体的装置和连续方法
|
JP6441828B2
(ja)
*
|
2013-03-04 |
2018-12-19 |
ブイティーブイ・セラピューティクス・エルエルシー |
安定なグルコキナーゼ活性化剤組成物
|
WO2014160177A2
(en)
|
2013-03-13 |
2014-10-02 |
Exelixis, Inc. |
Quinazoline inhibitors of pi3k
|
ES2743465T3
(es)
|
2013-03-15 |
2020-02-19 |
Glaxosmithkline Biologicals Sa |
Composición que contiene derivados fosfato de aminoalquil glucosaminida tamponados y su uso para potenciar una respuesta inmunitaria
|
KR102499439B1
(ko)
|
2013-03-15 |
2023-02-13 |
맨카인드 코포레이션 |
미세결정성 디케토피페라진 조성물 및 방법
|
US9732068B1
(en)
|
2013-03-15 |
2017-08-15 |
GenSyn Technologies, Inc. |
System for crystalizing chemical compounds and methodologies for utilizing the same
|
WO2014160633A1
(en)
|
2013-03-24 |
2014-10-02 |
Xenoport, Inc. |
Pharmaceutical compositions of dimethyl fumarate
|
US20140303097A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US20140303098A1
(en)
|
2013-04-05 |
2014-10-09 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
US11813275B2
(en)
|
2013-04-05 |
2023-11-14 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
CN105377266A
(zh)
|
2013-04-18 |
2016-03-02 |
勃林格殷格翰国际有限公司 |
药物组合物、治疗方法及其用途
|
EP2994470B1
(en)
|
2013-05-09 |
2018-04-18 |
Principia Biopharma Inc. |
Pyrido[2,3-d]pyrimidine derivatives as fibroblast growth factor inhibitors
|
US9302977B2
(en)
|
2013-06-07 |
2016-04-05 |
Xenoport, Inc. |
Method of making monomethyl fumarate
|
WO2014203210A1
(en)
|
2013-06-20 |
2014-12-24 |
Glenmark Pharmaceuticals S.A. |
Nanoparticulate formulation comprising a trpa1 antagonist
|
WO2014205392A1
(en)
|
2013-06-21 |
2014-12-24 |
Xenoport, Inc. |
Cocrystals of dimethyl fumarate
|
CA2918369C
(en)
|
2013-07-18 |
2021-06-29 |
Mannkind Corporation |
Heat-stable dry powder pharmaceutical compositions and methods
|
CA2920488C
(en)
|
2013-08-05 |
2022-04-26 |
Mannkind Corporation |
Insufflation apparatus and methods
|
JP2016534133A
(ja)
|
2013-09-06 |
2016-11-04 |
ゼノポート,インコーポレイティド |
(n,n−ジエチルカルバモイル)メチル メチル(2e)ブト−2−エン−1,4−ジオエートの結晶形態、その合成方法及び使用
|
US20150079180A1
(en)
|
2013-09-18 |
2015-03-19 |
Xenoport, Inc. |
Nanoparticle compositions of dimethyl fumarate
|
GB201319791D0
(en)
|
2013-11-08 |
2013-12-25 |
Sigmoid Pharma Ltd |
Formulations
|
WO2015071841A1
(en)
|
2013-11-12 |
2015-05-21 |
Druggability Technologies Holdings Limited |
Complexes of dabigatran and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them
|
EP2878311A1
(en)
|
2013-11-27 |
2015-06-03 |
Freund Pharmatec Ltd. |
Solubility Enhancement for Hydrophobic Drugs
|
US10087151B2
(en)
|
2014-01-09 |
2018-10-02 |
The J. David Gladstone Institutes, A Testimentary Trust Established Under The Will Of J. David Gladstone |
Substituted benzoxazine and related compounds
|
US9808428B2
(en)
|
2014-01-14 |
2017-11-07 |
Board Of Regents Of The University Of Nebraska |
Compositions and methods for the delivery of therapeutics
|
WO2015108783A1
(en)
|
2014-01-16 |
2015-07-23 |
The Brigham And Women's Hospital, Inc. |
Targeted delivery of immunoregulatory drugs
|
KR20220027271A
(ko)
|
2014-02-21 |
2022-03-07 |
프린시피아 바이오파마, 인코퍼레이티드 |
Btk 억제제의 염 및 고체 형태
|
EP3114124A1
(en)
|
2014-03-03 |
2017-01-11 |
Principia Biopharma, Inc. |
BENZIMIDAZOLE DERIVATIVES AS RLK and ITK INHIBITORS
|
WO2015134608A1
(en)
|
2014-03-05 |
2015-09-11 |
Nanotherapeutics, Inc. |
Compositions and methods for oral delivery of encapsulated 3-aminopyridine-2-carboxaldehyde particles
|
US9999672B2
(en)
|
2014-03-24 |
2018-06-19 |
Xenoport, Inc. |
Pharmaceutical compositions of fumaric acid esters
|
US10307464B2
(en)
|
2014-03-28 |
2019-06-04 |
Mannkind Corporation |
Use of ultrarapid acting insulin
|
MX2016013600A
(es)
|
2014-04-25 |
2017-04-27 |
Exelixis Inc |
Método para tratar adenocarcinoma de pulmón.
|
CN107072976A
(zh)
|
2014-05-12 |
2017-08-18 |
葛兰素史克知识产权第二有限公司 |
用于治疗传染性疾病的包含Danirixin的药物组合物
|
US9526734B2
(en)
|
2014-06-09 |
2016-12-27 |
Iceutica Pty Ltd. |
Formulation of meloxicam
|
US9550789B2
(en)
|
2014-06-18 |
2017-01-24 |
Demerx, Inc. |
Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them
|
WO2015195950A1
(en)
|
2014-06-20 |
2015-12-23 |
Principia Biophamram Inc. |
Lmp7 inhibitors
|
KR102493854B1
(ko)
|
2014-06-25 |
2023-01-30 |
글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 |
(s)-6-((1-아세틸피페리딘-4-일)아미노)-n-(3-(3,4-디히드로이소퀴놀린-2(1h)-일)-2-히드록시프로필)피리미딘-4-카르복스아미드의 결정질 염
|
PL3174535T3
(pl)
*
|
2014-08-01 |
2019-09-30 |
Glenmark Pharmaceuticals S.A. |
Preparat nanocząstkowy zawierający inhibitor mpges-1
|
PT3508196T
(pt)
*
|
2014-08-18 |
2021-08-25 |
Alkermes Pharma Ireland Ltd |
Composições de pró-fármaco de aripiprazol
|
US10016415B2
(en)
*
|
2014-08-18 |
2018-07-10 |
Alkermes Pharma Ireland Limited |
Aripiprazole prodrug compositions
|
WO2016033549A2
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
(17-ß)-3-OXOANDROST-4-EN-17-YL TRIDECANOATE COMPOSITIONS AND METHODS OF THEIR PREPARATION AND USE
|
WO2016033556A1
(en)
|
2014-08-28 |
2016-03-03 |
Lipocine Inc. |
BIOAVAILABLE SOLID STATE (17-β)-HYDROXY-4-ANDROSTEN-3-ONE ESTERS
|
KR20170054429A
(ko)
|
2014-09-03 |
2017-05-17 |
제네세규스 인코포레이티드 |
치료용 나노입자 및 관련 조성물, 방법, 및 시스템
|
AU2015313894A1
(en)
|
2014-09-08 |
2017-03-23 |
Glaxosmithkline Intellectual Property Development Limited |
Crystalline forms of 2-(4-(4-ethoxy-6-oxo-1,6-dihydropyridin-3-yl)-2-fluorophenyl)-n-(5-(1,1,1-trifluoro-2-methylpropan-2-yl)isoxazol-3-yl)acetamide
|
PT3201203T
(pt)
|
2014-09-29 |
2021-08-09 |
Takeda Pharmaceuticals Co |
Forma cristalina de 1-(1-metil-1h-pirazol-4-il)-n-((1r,5s,7s)-9-metil-3-oxa-9-azabiciclo[3.3.1]nonan-7-il)-1hindol-3-carboxamida
|
US10561806B2
(en)
|
2014-10-02 |
2020-02-18 |
Mannkind Corporation |
Mouthpiece cover for an inhaler
|
EP3203995A4
(en)
|
2014-10-09 |
2019-05-15 |
Board of Regents of the University of Nebraska |
COMPOSITIONS AND METHODS FOR DELIVERY OF THERAPEUTIC AGENTS
|
BR112017009510A2
(pt)
|
2014-11-07 |
2017-12-19 |
Sigmoid Pharma Ltd |
composições compreendendo ciclosporina
|
US11304902B2
(en)
*
|
2014-11-25 |
2022-04-19 |
Curadigm Sas |
Pharmaceutical compositions, preparation and uses thereof
|
MA41142A
(fr)
|
2014-12-12 |
2017-10-17 |
Amgen Inc |
Anticorps anti-sclérostine et utilisation de ceux-ci pour traiter des affections osseuses en tant qu'élements du protocole de traitement
|
CN107530383A
(zh)
|
2015-01-09 |
2018-01-02 |
埃图比克斯公司 |
用于埃博拉病毒疫苗接种的方法和组合物
|
CN104587457B
(zh)
*
|
2015-01-13 |
2017-03-22 |
广东海大畜牧兽医研究院有限公司 |
一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
|
US10166197B2
(en)
|
2015-02-13 |
2019-01-01 |
St. John's University |
Sugar ester nanoparticle stabilizers
|
JP2018507209A
(ja)
|
2015-02-20 |
2018-03-15 |
サイテック インダストリーズ インコーポレイテッド |
ジアルキルスルホスクシナート組成物、製造方法、および使用方法
|
JP7149076B2
(ja)
|
2015-03-03 |
2022-10-06 |
ファーマサイクリックス エルエルシー |
ブルトン型チロシンキナーゼ阻害剤の薬学的製剤
|
CA2980730A1
(en)
|
2015-03-23 |
2016-09-29 |
The Brigham And Women's Hospital, Inc. |
Tolerogenic nanoparticles for treating diabetes mellitus
|
CA3019769C
(en)
|
2015-04-21 |
2021-10-12 |
Sunovion Pharmaceuticals Inc. |
Methods of treating parkinson's disease by administration of apomorphine to an oral mucosa
|
CA2985652C
(en)
|
2015-05-14 |
2020-03-10 |
Gerald W. FISHER |
Rapid methods for the extraction of nucleic acids from biological samples
|
US10538517B2
(en)
|
2015-05-22 |
2020-01-21 |
Principia Biopharma, Inc. |
Quinolone derivatives as FGFR inhibitors
|
EA039006B1
(ru)
|
2015-06-03 |
2021-11-19 |
Принсипиа Биофарма Инк. |
Ингибиторы тирозинкиназы
|
TW201718572A
(zh)
|
2015-06-24 |
2017-06-01 |
普林斯匹亞生物製藥公司 |
酪胺酸激酶抑制劑
|
RU2018101431A
(ru)
|
2015-07-02 |
2019-08-05 |
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед |
Ингибиторы индоламин-2,3-диоксигеназы
|
WO2017004609A1
(en)
|
2015-07-02 |
2017-01-05 |
Exelixis, Inc. |
Thiadiazole modulators of s1p and methods of making and using
|
WO2017004610A1
(en)
|
2015-07-02 |
2017-01-05 |
Exelixis, Inc. |
Tercyclic s1p3-sparing, s1p1 receptor agonists
|
WO2017004608A1
(en)
|
2015-07-02 |
2017-01-05 |
Exelixis, Inc. |
Oxadiazole modulators of s1p methods of making and using
|
US20180194799A1
(en)
|
2015-07-28 |
2018-07-12 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Betuin derivatives for preventing or treating hiv infections
|
WO2017017609A1
(en)
|
2015-07-28 |
2017-02-02 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Betuin derivatives for preventing or treating hiv infections
|
EP3353167B1
(en)
|
2015-09-24 |
2020-06-24 |
GlaxoSmithKline Intellectual Property (No. 2) Limited |
Modulators of indoleamine 2,3-dioxygenase
|
CN108368049A
(zh)
|
2015-09-24 |
2018-08-03 |
葛兰素史克知识产权开发有限公司 |
吲哚胺2,3-双加氧酶的调节剂
|
KR20180054826A
(ko)
|
2015-09-24 |
2018-05-24 |
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 |
Hiv 성숙 억제 활성을 갖는 화합물
|
AU2016338672A1
(en)
|
2015-10-16 |
2018-04-12 |
Marinus Pharmaceuticals, Inc. |
Injectable neurosteroid formulations containing nanoparticles
|
WO2017130156A1
(en)
|
2016-01-27 |
2017-08-03 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Ingenol analogs, pharmaceutical compositions and methods of use thereof
|
EP3416616B1
(en)
|
2016-02-17 |
2021-08-04 |
Alkermes Pharma Ireland Limited |
Compositions of multiple aripiprazole prodrugs
|
WO2017142947A1
(en)
|
2016-02-17 |
2017-08-24 |
Global Blood Therapeutics, Inc. |
Histone methyltransferase inhibitors
|
EP3426674A4
(en)
|
2016-03-09 |
2019-08-14 |
Blade Therapeutics, Inc. |
CYCLIC KETO AMID COMPOUNDS AS CALPAIN MODULATORS AND METHOD FOR THE PRODUCTION AND USE THEREOF
|
GB201604124D0
(en)
|
2016-03-10 |
2016-04-27 |
Ucb Biopharma Sprl |
Pharmaceutical formulation
|
US10682340B2
(en)
|
2016-06-30 |
2020-06-16 |
Durect Corporation |
Depot formulations
|
AU2017290143A1
(en)
|
2016-06-30 |
2019-02-21 |
Durect Corporation |
Depot formulations
|
US20190328900A1
(en)
|
2016-07-01 |
2019-10-31 |
Glaxosmithkline Intellectual Property Development Limited |
Antibody-drug conjugates and therapeutic methods using the same
|
WO2018009417A1
(en)
|
2016-07-05 |
2018-01-11 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
KR102518846B1
(ko)
|
2016-08-11 |
2023-04-05 |
오비드 테라퓨틱스 인크. |
간질 장애의 치료를 위한 방법 및 조성물
|
IL264664B2
(en)
|
2016-08-19 |
2023-03-01 |
Orasis Pharmaceuticals Ltd |
Ophthalmic pharmaceutical preparations and uses related to them
|
US10391105B2
(en)
|
2016-09-09 |
2019-08-27 |
Marinus Pharmaceuticals Inc. |
Methods of treating certain depressive disorders and delirium tremens
|
WO2018049324A1
(en)
|
2016-09-12 |
2018-03-15 |
Numerate, Inc. |
Monocyclic compounds useful as gpr120 modulators
|
KR102340311B1
(ko)
|
2016-09-13 |
2021-12-20 |
쿄와 기린 가부시키가이샤 |
의약 조성물
|
WO2018064119A1
(en)
|
2016-09-28 |
2018-04-05 |
Blade Therapeutics, Inc. |
Calpain modulators and therapeutic uses thereof
|
BR112019007258B1
(pt)
|
2016-10-11 |
2022-07-26 |
Dsm Ip Assets B.V. |
Processo para a preparação de uma dispersão aquosa de um absorvedor de uv orgânico insolúvel nanométrico
|
US11559530B2
(en)
|
2016-11-28 |
2023-01-24 |
Lipocine Inc. |
Oral testosterone undecanoate therapy
|
US20180317486A1
(en)
|
2016-12-16 |
2018-11-08 |
Koppers Performance Chemicals Inc. |
Wood preservative and method for producing same
|
EP4063358B1
(en)
|
2016-12-22 |
2024-05-22 |
Global Blood Therapeutics, Inc. |
Histone methyltransferase inhibitors
|
EP3571208B1
(en)
|
2017-01-18 |
2021-03-10 |
Principia Biopharma Inc. |
Immunoproteasome inhibitors
|
KR102645511B1
(ko)
|
2017-04-10 |
2024-03-08 |
시에라 온코로지 엘엘씨 |
종양 성장을 저해하는 CHK1(SRA737)/PARPi 조합 방법
|
JP7249508B2
(ja)
|
2017-04-11 |
2023-03-31 |
ジーエスエヌオー セラピューティクス, インコーポレイテッド |
カルバゾール化合物及びその使用法
|
JP2020517578A
(ja)
|
2017-04-21 |
2020-06-18 |
バイオ−シネクティクス インク.Bio−Synectics Inc. |
脂質を製粉工程の潤滑剤として用いる活性物質のナノ粒子の製造方法
|
JP7225125B2
(ja)
|
2017-06-09 |
2023-02-20 |
グローバル ブラッド セラピューティクス インコーポレイテッド |
ヒストンメチルトランスフェラーゼ阻害剤としてのアザインドール化合物
|
PE20200336A1
(es)
|
2017-07-14 |
2020-02-14 |
Janssen Pharmaceutica Nv |
Formulaciones a largo plazo
|
CN111372927A
(zh)
|
2017-08-15 |
2020-07-03 |
全球血液疗法股份有限公司 |
作为组蛋白甲基转移酶抑制剂的三环化合物
|
WO2019036384A1
(en)
|
2017-08-15 |
2019-02-21 |
Global Blood Therapeutics, Inc. |
TRICYCLIC COMPOUNDS AS HISTONE INHIBITORS METHYLTRANSFERASES
|
WO2019087016A1
(en)
|
2017-10-30 |
2019-05-09 |
Glaxosmithkline Intellectual Property Development Limited |
Compounds useful in hiv therapy
|
DK3710457T3
(da)
|
2017-11-16 |
2022-10-24 |
Principia Biopharma Inc |
Immunproteasomhæmmere
|
CN111491938B
(zh)
|
2017-11-16 |
2024-05-24 |
普林斯匹亚生物制药公司 |
免疫蛋白酶体抑制剂
|
CA3126348A1
(en)
|
2018-01-12 |
2020-07-18 |
Board Of Regents Of The University Of Nebraska |
Antiviral prodrugs and formulations thereof
|
DE102018103528A1
(de)
|
2018-02-16 |
2019-08-22 |
Friedrich-Alexander-Universität Erlangen-Nürnberg |
Suspension nanoskaliger, organischer Partikel und Verfahren zu ihrer Herstellung
|
WO2019169017A1
(en)
|
2018-02-28 |
2019-09-06 |
Bioxiness Pharmaceuticals, Inc. |
Chemotherapeutic agents
|
WO2019169029A1
(en)
|
2018-02-28 |
2019-09-06 |
Bioxiness Pharmaceuticals, Inc. |
Target specific chemotherapeutic agents
|
EP3762104A2
(en)
*
|
2018-03-07 |
2021-01-13 |
ST IP Holding AG |
Combination compositions and therapies comprising 4-methyl-5-(pyrazin-2-yl)-3h-1,2-dithiole-3-thione, and methods of making and using same
|
US20200407393A1
(en)
|
2018-03-07 |
2020-12-31 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Medical Use
|
CA3093457A1
(en)
|
2018-03-30 |
2019-10-03 |
Amgen Inc. |
C-terminal antibody variants
|
CA3132832A1
(en)
|
2018-04-09 |
2019-10-17 |
Howard E. Gendelman |
Antiviral prodrugs and formulations thereof
|
JPWO2019240104A1
(ja)
|
2018-06-11 |
2021-06-24 |
大塚製薬株式会社 |
デラマニド含有組成物
|
CA3093025A1
(en)
|
2018-06-12 |
2019-12-19 |
Vtv Therapeutics Llc |
Therapeutic uses of glucokinase activators in combination with insulin or insulin analogs
|
US20220117993A1
(en)
|
2018-08-09 |
2022-04-21 |
Glaxosmithkline Intellectual Property (No. 2) Limited |
Compounds Useful in HIV Therapy
|
JP2021536444A
(ja)
|
2018-08-30 |
2021-12-27 |
グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited |
Hiv療法に有用な化合物
|
WO2020121006A2
(en)
|
2018-10-19 |
2020-06-18 |
Innostudio Inc. |
Method and apparatus to produce nanoparticles in an ostwald ripening flow device with tubes of variable path length
|
BR112021010353A2
(pt)
|
2018-11-30 |
2021-08-31 |
Glaxosmithkline Intellectual Property Development Limited |
Compostos úteis em terapia hiv
|
WO2020118142A1
(en)
|
2018-12-07 |
2020-06-11 |
Marinus Pharmaceuticals, Inc. |
Ganaxolone for use in prophylaxis and treatment of pospartum depression
|
MX2021008748A
(es)
|
2019-01-22 |
2022-01-24 |
The Roskamp Inst |
Derivados de aminoacidos para el tratamiento de enfermedades inflamatorias.
|
WO2020167912A1
(en)
|
2019-02-13 |
2020-08-20 |
The Brigham And Women's Hospital, Inc. |
Anti-peripheral lymph node addressin antibodies and uses thereof
|
CN113811360A
(zh)
|
2019-03-06 |
2021-12-17 |
葛兰素史密斯克莱知识产权(第2 号)有限公司 |
用于hiv治疗的化合物
|
FI3952995T3
(fi)
|
2019-04-12 |
2023-10-26 |
Riboscience Llc |
Bisyklisiä heteroaryylijohdannaisia ektonukleotidipyrofosfataasifosfodiesteraasi-1:n inhibiittoreina
|
CA3145923A1
(en)
|
2019-08-05 |
2021-02-11 |
David Czekai |
Ganaxolone for use in treatment of status epilepticus
|
WO2021024114A1
(en)
|
2019-08-08 |
2021-02-11 |
Glaxosmithkline Intellectual Property (No.2) Limited |
4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
|
US20220298160A1
(en)
|
2019-08-28 |
2022-09-22 |
Glaxosmithkline Intellectual Property (No.2) Limited |
Compounds useful in hiv therapy
|
WO2021072325A1
(en)
|
2019-10-11 |
2021-04-15 |
Corbus Pharmaceuticals, Inc. |
Compositions of ajulemic acid and uses thereof
|
CN114828889A
(zh)
|
2019-12-06 |
2022-07-29 |
马瑞纳斯制药公司 |
用于治疗结节性硬化症的加奈索酮
|
JP2023510604A
(ja)
|
2020-01-20 |
2023-03-14 |
ジェンザイム・コーポレーション |
再発型多発性硬化症(rms)用の治療用チロシンキナーゼ阻害剤
|
WO2021195319A1
(en)
|
2020-03-26 |
2021-09-30 |
Plx Opco Inc. |
PHARMACEUTICAL CARRIERS CAPABLE OF pH DEPENDENT RECONSTITUTION AND- METHODS FOR MAKING AND USING SAME
|
US20230233576A1
(en)
|
2020-04-17 |
2023-07-27 |
Genzyme Corporation |
Eclitasertib for use in treating conditions involving systemic hyperinflammatory response
|
AU2021261327A1
(en)
|
2020-04-22 |
2022-12-22 |
Principia Biopharma Inc. |
Treatment of acute respiratory distress syndrome and other disorders involving cytokine storm using BTK inhibitors
|
EP3928772A1
(en)
|
2020-06-26 |
2021-12-29 |
Algiax Pharmaceuticals GmbH |
Nanoparticulate composition
|
US20230355606A1
(en)
|
2020-07-09 |
2023-11-09 |
Janssen Pharmaceutica Nv |
Long-acting formulations
|
EP4178540A1
(en)
|
2020-07-09 |
2023-05-17 |
JANSSEN Pharmaceutica NV |
Long-acting formulations
|
KR20230038521A
(ko)
|
2020-07-09 |
2023-03-20 |
얀센 파마슈티카 엔.브이. |
장기 작용 제형
|
US11980636B2
(en)
|
2020-11-18 |
2024-05-14 |
Jazz Pharmaceuticals Ireland Limited |
Treatment of hematological disorders
|
CN112451520B
(zh)
*
|
2020-12-31 |
2021-10-15 |
江苏宇锐医药科技有限公司 |
一种缬沙坦氨氯地平组合物及其制备方法
|
EP4298105A1
(en)
|
2021-02-23 |
2024-01-03 |
VIIV Healthcare Company |
Compounds useful in hiv treatment
|
WO2023023473A1
(en)
|
2021-08-16 |
2023-02-23 |
Sierra Oncology, Inc. |
Methods of using momelotinib to treat chronic kidney disease
|
US20230077636A1
(en)
*
|
2021-08-31 |
2023-03-16 |
Natsar Pharmaceuticals, Inc. |
Intravenous formulations of rk-33
|
WO2023239727A1
(en)
|
2022-06-06 |
2023-12-14 |
The Usa, As Represented By The Secretary, Dept. Of Health And Human Services |
Lats inhibitors and uses thereof
|
WO2023244672A1
(en)
|
2022-06-14 |
2023-12-21 |
Assembly Biosciences, Inc. |
2-(imidazo[1, 2-a]1,8-naphthyridin-8-yl)-1,3,4-oxadiazole derivatives as enhancers of innate immune response for the treatment of viral infections
|
WO2024006406A1
(en)
|
2022-06-30 |
2024-01-04 |
Genzyme Corporation |
Therapeutic tyrosine kinase inhibitors for multiple sclerosis and myasthenia gravis
|
WO2024010782A1
(en)
|
2022-07-06 |
2024-01-11 |
Vividion Therapeutics, Inc. |
Pharmaceutical compositions comprising wrn helicase inhibitors
|
WO2024010784A1
(en)
|
2022-07-06 |
2024-01-11 |
Vividion Therapeutics, Inc. |
Pharmaceutical compositions comprising wrn helicase inhibitors
|
WO2024068693A1
(en)
|
2022-09-28 |
2024-04-04 |
Janssen Pharmaceutica Nv |
Long-acting formulations
|
WO2024068699A1
(en)
|
2022-09-28 |
2024-04-04 |
Janssen Pharmaceutica Nv |
Long-acting formulations
|
US20240173313A1
(en)
|
2022-10-11 |
2024-05-30 |
Genzyme Corporation |
Therapeutic tyrosine kinase inhibitors for multiple sclerosis
|
CN115844821B
(zh)
*
|
2023-01-03 |
2024-05-17 |
江苏知原药业股份有限公司 |
一种地奈德纳米晶混悬液、制备方法及其应用
|